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ABSTRACT
Diet, Inflammation, Gut Microbiome, and Mental Health
By
Ashley R. Polokowski

Advisor: Laura C. Reigada

Omega-3 fatty acids (ω-3 FAs) are an essential fatty acid necessary for healthy development in
mammals. They possess anti-inflammatory properties and have more recently been shown to
impact gut microbiota, both factors hypothesized to be associated with depression and anxiety.
Thus, empirical efforts have begun to examine the benefit of ω-3 FAs as a treatment option for
various psychological disorders. Although there is evidence that ω-3 FAs have favorable
outcomes on depressive symptoms, the relationship between ω-3 FAs and anxiety and the
pathways by which ω-3 FAs produce beneficial health effects are poorly understood. Both
inflammation and the gut microbiome have an impact in the development of anxiety and
depression, thus these factors may play a fundamental role as mechanisms explaining the
beneficial effect of ω-3 FAs on psychological health. This study aims to 1) to examine the crosssectional relationship between ω-3 FAs; gut microbiome bacteria and inflammatory markers; and
stress, anxiety, and depressive symptoms; and 2) to examine if the gut microbiome and
inflammatory markers mediate the relationship between ω-3 intake and stress, anxiety and
depressive symptoms. Results indicate that higher levels of omega-3 index and DHA were
associated with lower reported trait-anxiety symptoms, depressive symptoms, and lower
concentrations of the inflammatory marker IL-1β. There was no evidence that gut bacteria or
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inflammation mediated the relationship between ω-3 FAs and stress, anxiety, or depression
symptoms, but several significant associations were noted. In particular, findings suggest that
increased omega-3 index and DHA levels predicted fewer trait-anxiety and depression
symptoms. Additional research is warranted to elucidate the interplay of mechanisms that may
explain the impact of ω-3 FAs on mental health outcomes.
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CHAPTER 1: INTRODUCTION
Diet and Mental Health
One of the most under-recognized factors in the development of mental health disorders
is the role of nutrition. It is well established that unhealthy dietary habits contribute to negative
physical health consequences worldwide, and it is estimated that the U.S. Department of
Agriculture spends millions of dollars annually on nutritional education programs (e.g., The
Expanded Food and Nutrition Education Program) to improve dietary habits (United States
Department of Agriculture, 2016).
In addition to the associated physiological health consequences, accumulating evidence
supports that diet can play a role in the development, management and prevention of various
mental health problems such as anxiety and depression. A global meta-analysis showed that
higher consumption of fruits, vegetables, fish, and grains were associated with lower odds of
developing depression in adults (Lai et al., 2013). This effect was also found in older adults (≥60
years) in a cross-sectional study comparing clinically depressed and non-depressed older adults
(≥60 years) (Payne, Steck, George, & Steffens, 2012).
The impact of diet on psychological health has also started to be explored in child and
adolescent populations. A systematic review found a significant association between unhealthy
diet and poorer mental health outcomes (e.g., depression, anxiety) across seven countries around
the world (O’Neil et al., 2014). In a recent cross-sectional study of Iranian adolescent girls, those
whom consumed more pro-inflammatory diets (e.g., high in carbohydrates and unhealthy fats)
had greater levels of stress (Shivappa, Hebert, & Rashidkhani, 2017).
Aside from anxiety and depressive symptoms, diet has also been shown to affect other
dimensions of mental health such as neuroplasticity (Murphy et al., 2014), protection against
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cognitive decline (Naqvi et al., 2011), development of subcortical brain structures, and verbal IQ
(Isaacs et al., 2008). Collectively, these associations have led researchers to investigate the role
of nutrition and nutritional supplements on treating mental health disorders including depression
and anxiety.
Omega-3 Fatty Acids (ω-3 FAs)
Omega-3 fatty acids are acknowledged as a necessary component of a healthy lifestyle
because they possess numerous physical and mental health benefits (Ruxton, Reed, Simpson, &
Millington, 2007).
Omega-3 fatty acids (referred to as ω-3 FAs) and omega-6 fatty acids (referred to as ω-6
FAs), are two major classes of long chain polyunsaturated fatty acids (PUFA) that contain two or
more double bonds. Each of these PUFAs are essential fatty acids (EFA), meaning they cannot
be synthesized by mammals and must be obtained by the diet but are physiologically necessary
for normal mammalian cell functioning (Innis, 1991), including central nervous system
development (Perica & Delaš, 2011). The essential fatty acid alpha-linolenic acid (ALA) is the
precursor to the ω-3 FAs, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The
essential fatty acid linoleic acid (LA) is the precursor to the ω-6 FA arachidonic acid (AA). A
balance of ω-3 and ω-6 FAs are necessary for proper health and development (Simopoulos,
2002).
The three main ω-3 FAs important to human functioning are: ALA with an 18-carbon
chain, EPA with a 20-carbon chain, and DHA with a 22-carbon chain. Each of the ω-3 FAs can
be obtained from dietary sources, ALA from plant-based oils (e.g., seeds, nuts) and EPA and
DHA from marine based oils (e.g., fish, algae). In addition to obtaining it from dietary sources,
humans can convert the essential fatty acid, ALA, into the longer chain ω-3s, EPA and DHA
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although this conversion is inefficient (Anderson & Ma, 2009; Burdge & Calder, 2005). Within
the brain of mammals, DHA is the most common ω-3 FA and plays a critical role in the
development and function of the brain throughout the life span (Innis, 2007). EPA and DHA
have both been deemed necessary for healthy brain function and retina development, are a
protective factor against coronary heart disease and diabetes, and are associated with reduced
cancer growths (Narayan, Miyashita, & Hosakawa, 2006).
Over the past century, there has been a drastic shift in dietary patterns, including the
substantially increased consumption of ω-6 fatty acids, due to the large amount of linoleic acidenriched vegetable oils in the food supply, and subsequent deficiency of ω-3 FAs in the Western
diet (Simopoulos, 2002). The consumption of excessive amounts of ω-6 FAs paired with
depleted levels of ω-3 FAs in many human diets foster the development of numerous diseases
such as inflammatory diseases, cancer, and cardiovascular disease (Simopoulos, 2001). In a
study analyzing risk assessment of dietary risk factors in preventable causes of death in the
United States, results demonstrate that high dietary trans-fatty acid content, high dietary salt
content, and low ω-3 FA content were the dietary risks found to have the largest mortality effects
(Danaei et al., 2009).
Omega-3 FAs show such promise in improving health that they are being used as a
treatment option for various inflammatory diseases such as rheumatoid arthritis (James &
Cleland, 1997), Crohn’s disease (Belluzzi et al., 1996), and asthma (Broughton, Johnson, Pace,
Liebman, & Kleppinger, 1997). Furthermore, preclinical research has noted a fundamental role
of ω-3FAs within brain functioning and mental health, in which a lack of these fatty acids in the
brain can stimulate anxious and depressive behaviors (Müller et al., 2015). Although the
literature has begun to acknowledge the positive impact of ω-3 FAs on chronic mental health
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conditions like depression and anxiety, the pathways by which ω-3 FAs demonstrate beneficial
effects on mental health is not as well-defined.
ω-3 FAs and Depression
A growing literature suggests that ω-3 FA supplementation has therapeutic benefits in
reducing depressive symptoms. Early findings in rodents indicate that ω-3 FAs play a favorable
role on depressive behaviors. Rats fed a diet deficient in ω-3 FAs, spent significantly more time
immobile on the forced swim test for depression compared to rats fed ω-3 adequate diets (DeMar
et al., 2006; Levant et al., 2008). Furthermore, when rats are supplemented with additional ω-3
FAs in their diet, they display significantly decreased immobility compared to rats fed a normal
diet (Ferraz et al., 2008; Huang et al., 2008) indicating ω-3 FA supplementation may assist in
alleviating depressive behavior in rodents. The literature is mixed when describing the
associations of ω-3 FAs on depression in human subjects. Data from a health survey of
Norwegian adults revealed that those who consume cod liver oil which is high in ω-3 FAs were
less likely to experience depression (Raeder et al., 2007). Similar results were found in pregnant
English women, where lower ω-3 FA intake was associated with increased depressive symptoms
(Golding et al., 2009). However, a recent review of 26 studies reports that ω-3 FAs only promote
a small to moderate difference in depressive symptoms (Appleton et al., 2007). Other researchers
have discovered more specific findings when examining this relationship. For instance, ω-3 FAs
may be beneficial to depressive symptoms for males but not females (Murakami et al., 2010).
Likewise, meta-analyses of experimental studies are also mixed. One meta-analysis examining
13 randomized placebo-controlled trials found no relationship between depression and ω-3 FAs
(Bloch & Hannestad, 2012) while another meta-analysis reviewing 13 randomized placebocontrolled trials describe a significant meta-analytic effect (Mocking et al., 2016). A more
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nuanced meta-analysis investigating randomized controlled trials (RCT) of ω-3 FAs as treatment,
separated patients with a major depressive disorder (MDD) (n = 11) from patients with
depressive symptoms without a MDD diagnosis (n = 8), and found that ω-3 FAs demonstrated
clinical benefits as compared to placebo in both MDD groups (Grosso et al. 2014b).
ω-3 FAs and Anxiety
The effects of ω-3 FAs on anxiety have been less studied than depression and the
research is limited to mainly correlational studies, with only a handful of intervention studies in
human subjects. In the animal literature, ω-3 supplementation has been shown to decrease
anxiety in non-humans. For instance, a DHA enriched diet has shown to reduce anxiety in mice
as measured by the light-dark transition test (Carrié et al., 2002), while a diet enriched with EPA
has shown to decrease anxious behavior (e.g., less time spent in arms of elevated maze) in rats
(Song, Li, Leonard, & Horrobin, 2003). The impact of ω-3 FAs has also been examined among
pregnant rats. Pregnant rats assigned to a ω-3 enriched diet displayed decreased anxiety-like
behavior (e.g., increased time spent in the open arms of the elevated plus maze test) (Chen & Su,
2012). Another study by Chen & Su (2013) tested whether a diet deficient in ω-3 at either a preweaning stage (embryo-weaning at 3 weeks) as compared to a post-weaning stage (3-10 weeks)
would lead to anxiety like behaviors in male offspring. It was found that an ω-3 deficient diet
during the pre-weaning period increased anxiety like behavior in the offspring later in life, as
compared to the offspring fed the ω-3 deficient diet during the post-weaning stage. These results
suggest the importance of ω-3 consumption during pregnancy to ensure healthy development and
to ameliorate anxiety.
Although limited, within human subjects, findings of observational and experimental
studies examining ω-3 FAs on anxiety indicate encouraging effects. Similar to animal studies, ω-
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3 FAs have been shown to have therapeutic benefits for anxiety symptoms in human samples
(Ross, 2009). Several studies have examined the relationship between ω-3 FAs and anxiety in
women. In a community-based sample of Australian women, Jacka and colleagues (2013)
discovered that women with high levels of DHA intake had a 50% reduced likelihood of a
current anxiety disorder (e.g., panic disorder, agoraphobia, social phobia, specific phobia,
generalized anxiety disorder). Indeed, pregnant women with lower levels of DHA may have a
stronger likelihood of having a current anxiety disorder compared to pregnant women with
higher levels of DHA (Verly-Miguel et al., 2015). In addition, pregnant women who consumed
diets that included ω-3 FAs were more likely to have lower levels of self-reported anxiety
symptoms as compared to pregnant women who did not consume any ω-3 FAs in their diet (dos
Santos Vaz et al., 2013). Further, having an anxiety disorder diagnosis, and the severity of the
anxiety disorder were associated with the lowest amount of EPA and DHA levels (Liu et al.,
2013). One study investigated the effects of ω-3 FAs on eleven patients diagnosed with
obsessive-compulsive disorder (OCD). Patients were randomly assigned to receive six weeks of
a placebo and six weeks of EPA 2 grams, in counterbalanced order (Fux, Benjamin, & Nemets,
2004). Results demonstrated that as compared to the placebo, supplementing with EPA did not
produce any differences in anxiety. One explanation for the lack of differences between the
supplements may be the fact that all participants were stabilized on a selective serotonin reuptake
inhibitor. Another study found that there were lower concentrations of ω-3 FAs in patients with
social anxiety disorder and that this was also associated with greater symptom severity compared
to a control group (Green, Hermesh, Monselise, Marom, Presburger, & Weizman, 2006). While
few experimental studies have been conducted, the research examining the impact of ω-3 FAs on
anxiety indicates promising results.
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Potential Pathways Mediating the Effect of ω-3 FAs on Depression and Anxiety
What is Inflammation?
Inflammation is a biological response to bodily injury or infection and is part of the
innate immune response (Calder, 2006). The inflammatory response allows immune cells such as
granulocytes, monocytes, and macrophages to destroy invading pathogens and remove cellular
debris to prepare for future repair. In addition, the inflammatory response involves a release of
cytokines, which are proteins produced by monocytes and macrophages to regulate immune and
inflammatory reactions (Zhang & An, 2009). However, a prolonged or uncontrollable
inflammatory response can result in tissue damage and lead to inflammatory diseases (Calder,
2006).
Importance of Inflammation on Depression and Anxiety
Mental health and inflammation have shown to be associated with one another, and it has
been theorized that the release of cytokines as a part of inflammatory response serves a critical
role in depression (Maes et al., 2009). Depression has been linked to increased production of
proinflammatory cytokines (e.g., TNF-α, IL-6). Two meta-analyses of cross-sectional studies
(Dowlati et al., 2010; Howren, Lamkin, Suls, 2009) suggest that inflammatory markers,
specifically cytokines TNF-α, IL-1, and IL-6, are elevated in depressed patients. Furthermore, a
meta-analysis of longitudinal studies shows a small but significant effect of C-reactive protein
(CRP) on depression (Valkanova et al., 2013). One recent study found that subjects with MDD
not on medication has significantly higher levels of IL-6 and TNF-α compared to control
subjects (Lindqvist et al., 2017).
The relationship between inflammation and anxiety has been less studied. However, one
study of older adults used autoregressive cross-lagged panel models to show that levels of CRP
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in dried blood spots significantly predicted not only depression, but also anxiety and stress five
years later (Das, 2016). Within an adolescent sample it has been found that there is a linear,
dose-dependent relationship between levels of CRP and percent of adolescents with GAD
(Khandaker, et al. 2016). Furthermore, the adolescents in the top third of serum CRP levels, were
five times more likely to develop GAD than those in the bottom third. Adolescents with
internalizing disorders (e.g., MDD, generalized anxiety disorder (GAD), separation anxiety
disorder, social anxiety disorder or panic disorder) demonstrate significantly higher IL-6 as
compared to adolescents without internalizing disorders (da Silva et al., 2017). As evidence
indicates that the inflammatory process may elicit anxiety and depressive symptoms and
disorders, it is important to explore novel approaches to analyze this relationship.
Relationship between ω-3 FAs and Inflammation
It has been established that ω-3 and ω-6 FAs play a role in inflammation as a metaanalysis of 68 randomized control trials (RCTs) discovered that ω-3 supplementation was
associated with reduced levels of tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), and
CRP in healthy participants as well as participants with chronic non-autoimmune diseases and
chronic autoimmune diseases (Li, Huang, Zheng, Wu, & Li, 2014). ω-3 and ω-6 FAs affect
inflammation by being metabolized into signaling molecules (Calder, 2006) that include
prostaglandins, thromboxanes, lipoxins, and leukotrienes (Smith, 1989) as well as protectins,
resolvins, and maresins (Serhan, Chiang, Dalli, & Levy, 2015). Increased consumption of ω-3
FAs have been found to suppress the release of proinflammatory eicosanoids and produce antiinflammatory eicosanoids, leading to reduced inflammation (Wall, Ross, Fitzgerald, & Stanton,
2010).
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Understanding how ω-3 FAs biologically interact with immune cells will elucidate how
they produce anti-inflammatory effects. Omega-3 FAs play many roles in immune cell
functioning such as modifying membrane proteins, modifying membrane composition and
fluidity of immune cells, influencing gene expression, and producing lipid mediators (Calder,
2008). Dietary PUFAs undergo a variety of enzymatic reactions before they are converted into
eicosanoids, or a family of fatty acids that act as local hormones and influence a variety of
biological functions including cell growth and metabolism (Smith, 1989). However, the longchain fatty acids and their functions depend on the PUFA that they originate from. The EFA
from the ω-6 series, LA (18:2n-6) is converted to the twenty-carbon long chain fatty acid AA
(20:4n-6) while the EFA from the ω-3 series, ALA (18:3n-3), is converted to the twenty-carbon
long chain fatty acid EPA (20:5n-3).
The relationship between ω-3 and ω-6 FAs is not always straightforward. Metabolites of
the twenty carbon ω-6 FA AA can exert proinflammatory or pro-resolving actions depending on
the specific metabolite and the context (Calder, 2006; Poorani et al., 2015). Prostaglandin E2, for
example, contributes not only to the initiation of inflammation (Ricciotti & FitzGerald, 2011) but
also to the resolution of inflammation by triggering the production of lipoxin A4, another
metabolite of AA (Chan & Moore, 2010; Poorani et al., 2015). Another twenty carbon ω-6 FA,
dihomo-γ-linolenic acid (DGLA) inhibits inflammation through its conversion to prostaglandin
E1. In contrast, the ω-3 FA EPA inhibits the initiation through its conversion to prostaglandin E3
(Wall, Ross, Fitzgerald, & Stanton, 2010). Moreover, the ω-3 FA DHA promotes the resolution
of inflammation through its conversion to resolvins, protectins, and maresins which are vital in
the resolution of inflammatory responses (Serhan, 2007). EPA also generates similar metabolites
in the presence of aspirin. These pro-resolving compounds assist the return of a tissue to
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homeostasis and downregulate proinflammatory cytokines (Bannenberg & Serhan, 2010;
Schwab, Chiang, Arita, & Serhan, 2007).
Overall, ω-6 FAs contribute both to the initiation, prevention, and resolution of
inflammation, while ω-3 FAs are more straightforwardly anti-inflammatory and pro-resolution.
Thus, a balanced ratio of consumption of ω-3 and ω-6 FAs is important. Currently, the western
diet has a high ω-6 to ω-3 ratio of approximately 20:1, fostering the development of various
diseases such as cardiovascular disease, obesity, and diabetes (Simopolous, 2016). The ideal
ratio of ω-6 to ω-3 is 4:1 or 1:1 (Simopoulos, 2008), or somewhere in between. Consumption of
fewer ω-6 or improving the intake of ω-3 from food or supplements may improve health by
supporting the proper regulation of inflammation.
Although the consumption of a balanced ratio of ω-3 and ω-6 FAs is important, the
measurement and reporting of this metric should be interpreted with caution. Harris (2006)
reports that a ratio does not allow one to have a clear picture of the absolute value of each of the
ω-3 and ω-6 FAs. Furthermore, ω-6 FAs have various physiological properties, which some
contributing to the resolution of inflammation and thus should not be compiled together into a
ratio with ω-3 FAs (Harris, 2006).
ω-3 FAs, Inflammation, and Mental Health
There has been an expansion of empirical research on the mechanisms underlying the
relationship between ω-3 FAs and depression (Müller et al., 2015; Su, Wang, & Pae, 2013), with
one hypothesized mechanisms of action being the inflammatory response. See Figure 1.
Decreased levels of ω-3 FAs have been found to increase the amount of proinflammatory
cytokines and increase depression and anxiety symptoms. For example, university students with
low levels of ω-3 FAs under stress displayed increased levels of inflammatory cytokines
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compared to controls (Maes, 2000). In addition, adult patients with clinical depression have
shown to have lower levels of ω-3 FAs and greater levels of inflammatory markers as compared
to control patients (Baek & Park, 2013). Compared to a control group, women with perinatal
depression displayed decreased levels of ω-3 FAs and significantly greater levels of TNF-α
(Chang et al., 2017).
The impact of ω-3 FAs in relation to inflammatory markers and anxiety symptoms have
been less studied. Kiecolt-Glaser and colleagues (2011) examined whether ω-3 FAs would
decrease proinflammatory cytokine (IL-6) and anxiety symptoms in a sample of 68 medical
students. It was found that the participants who received the ω-3 FA supplements demonstrated a
14% reduction in stimulated IL-6 and a 20% decrease in anxiety scores as compared to a
placebo. Although not significant, the authors note that there was a comparable reduction in
stimulated TNF-α levels as well.
What is the Gut Microbiome?
The human gut microbiome is a collection of trillions of microorganisms (e.g., bacteria,
fungi) that reside in the gastrointestinal tract. Each individual has a unique gut microbiome and
many factors influence the composition of the gut microbiome including age, sex, and dietary
habits. The nutritional value of food is influenced by the structure of an individual’s gut
microbiome, and food in turn shapes the microbiome (Kau et al., 2012). The gut microbiome
plays a notable role in physical and mental health and alterations within the gut microbiome are
associated with the development of various chronic conditions. Thus, it is hypothesized that in
addition to the inflammatory response, the gut microbiome may be a potential mechanism
underlying the relationship between ω-3 FAs and depression and anxiety.
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Importance of the Gut Microbiome for Depression and Anxiety
Additionally, developments have been made in the past decade regarding our
understanding of how the brain communicates with the human gastrointestinal tract. Recent
research highlights an expanded system: the brain-gut-microbiota axis, which posits that the
microbiota in the gut also impacts the central nervous system, which in turn influences
neurological functioning, inflammation, and emotion-related behaviors (Wong et al., 2016).
Although novel, there is already extensive research on the brain-gut axis and the
bidirectional relationship between the brain and the gastrointestinal tract (GIT) (Grenham et al.,
2011; Mayer, 2011). Studies of germ-free gnotobiotic mice (where only known strains of
microorganisms are present) show how essential the gut microbiota is not only to the
development of a healthy gut, but also to the development of a healthy central nervous system.
Animal studies show that when experiencing high levels of stress, animals have altered
microbiome profiles (Bailey et al., 2011; Cryan & Dinan, 2012). Furthermore, clinical studies
have shown that the administration of the probiotic, Lactobacillus rhamnosus, is associated with
reduced anxiety- and depressive-like behavior in rats (Bravo et al., 2011).
These studies have been expanded to human subjects and the gut microbiome appears to
play a large role in human cognitive and emotional functioning (Dinan, Stilling, Stanton, &
Cryan, 2015). Adults administered probiotics (Lactobacillus helveticus and Bifidobacterium
longum) demonstrated improved psychological distress symptoms over a 30-day period
(Messaoudi et al., 2011). In another human study, infants supplemented with probiotics had no
diagnosis of Asperger’s Syndrome and/or attention deficit hyperactivity disorder at the age of 13,
while 17% of children who received placebo formula developed a diagnosis of a developmental
disorder (Pärtty et al., 2015). Growing evidence suggests that the gut microbiome promotes or
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prevents inflammatory responses which in turn may lead to neuropsychiatric disorders
(Robertson et al., 2016).
Effect of ω-3 FAs on the Gut-Microbiome
Dietary habits have been found to largely influence the structure of the microbiome
(David et al., 2014; Kau, 2012). Novel evidence has shown that ω-3 FAs have a significant
impact on gut microbiota (Yu et al., 2014). One study found that mice supplemented with ω-3
FAs have more anti-inflammatory bacteria (e.g., lactobacillus and Bifidobacterium) compared to
mice with deficient ω-3 FA (Robertson et al., 2016) as well as decreased levels of inflammation
and improved gut microbiota profiles (Kaliannan et al., 2015; Myles et al., 2014). Another study
examining the impact of ω-3 FAs on gut microbiota in early-life stress found that ω-3 FA
supplementation restored the damaged gut microbiota of maternally separated female rats
(Pusceddu et al., 2015). Collectively, these findings imply that diet may influence inflammation
either directly or indirectly through alterations in the gut microbiome, which then may increase
risk for depression and anxiety.
Initial studies have examined how ω-3 FAs alter gut microbiota profiles mainly in animal
samples (e.g., mice, piglets) (Andersen, Mølbak, Thymann, Michaelsen, & Lauritzen, 2011; Yu
et al., 2014) with limited studies examining human samples (Andersen, Mølbak, Michaelsen, &
Lauritzen, 2011). Although the relationship between ω-3 FAs and the gut microbiome within
human samples is relatively unknown, studies are beginning to explore this association. One
study by Kankaanpää and colleagues (2002) found that probiotic supplemented formula led to
changes in PUFA composition among infants as compared to infants consuming regular formula.
For example, Bifidobacterium supplemented formula increased ALA through increased
absorption (Kankaanpää et al., 2002). Studies focus on a variety of bacteria and demonstrate
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mixed results; however, evidence reveals that ω-3 FAs have a therapeutic impact on gut bacteria
(Li et al., 2011), which may mediate the physical and psychological benefits of ω-3 FA. Further
investigation of these relationships is warranted within human samples given the implications on
mental health.
ω-3FAs, Gut-Microbiota, Inflammation and Mental Health
Many of the aforementioned studies suggest that ω-3 FAs affect mental health through
inflammatory responses or the gut-microbiota. However, the literature is beginning to look at the
dynamic interplay between these variables and how diet plays a critical role in the gut
microbiome, inflammatory responses, and mental health (Sandhu et al., 2017). One proposed
hypothesis by Logan and Katzman (2005) is that probiotics and ω-3 FAs may have a
bidirectional relationship, where ω-3 FAs may alter the types of gut bacteria produced and gut
bacteria can impact the amount of ω-3 FA levels. Furthermore, researchers have hypothesized
that the absence of healthy bacteria may lead to the initiation of the inflammatory response, and
consequently leading to depression (Berk et al., 2013). Based on the literature, it is our scientific
premise that ω-3 FAs can influence the gut microbiome by increasing healthy gut bacteria and
subsequently reducing inflammatory cytokines, leading to decreased anxiety and depressive
symptoms. This hypothesis suggests a serial mediation model can be tested, where the predictor
exerts an effect on the outcome through two mediators linked in a causal chain (Hayes, 2015).
Taken together, these pathways have the potential to explain the ways in which ω-3 FAs are
related to anxiety and depressive symptoms.
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Quality of Current Research
The present state of the research involving ω-3 FAs and mental health outcomes
demonstrate a great amount of heterogeneity. There are at least three important ways that future
research can test how ω-3 FAs may impact psychological health.
Stringent Testing of Dosage and Type of ω-3 FAs
Each type of ω-3 FA (i.e., ALA, EPA, and DHA) has a different biochemical make-up
and may have different implications on mental health outcomes over different periods of time.
Thus, controlling for the specific type of ω-3 FA administered and length of intervention would
enhance the literature allowing for more specific conclusions to be made. Moreover, studies
contain a wide range of dosages, although, most studies administer supplements higher than a
typical (or over the counter) ω-3 supplement which contains approximately 300 mg of EPA and
DHA combined (Wall et al., 2010). One meta-analysis concluded that when EPA
supplementation was 200-2200 mg more than DHA, beneficial effects were found in depressive
symptoms (Sublette, Ellis, Geant, & Mann, 2011). Currently, there are no established guidelines
reporting the ideal balance of ω-3 dosages for mental health symptoms.
Assessing Daily Dietary Intake
While administering ω-3 FAs to participants, intervention studies do not typically assess
the diet of their subjects. Utilizing food frequency questionnaires or food diaries would provide a
way to control for what participants consume in addition to the treatment intervention. This
would increase our understanding of the impact of ω-3 FAs on depression and anxiety, as dietary
sources contain different amounts of each type of ω-3 FA (Howe, Meyer, Record, & Baghurst,
2005; Wall et al., 2010). The predominant types of fatty acid consumed on a regular basis
depend on geographical region (Food and Agriculture Organization of the United Nations, 2010).
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For instance, dietary intake of ω-3 FAs will vary based on regional location such as a coastal or
non-coastal region (Al-Numair, Lewis, & Evans, 2005) which can influence research findings.
Consistent Measurement of Psychological Symptoms or Disorders
Reviews conducted by Su et al. (2015) and Grosso et al. (2014a) elucidate that metaanalyses done within this area of research are sensitive to heterogeneity among populations,
measures, and interventions may not conclude accurate results. However, when the literature
systematically reviews a homogenous sample, such as patients diagnosed with MDD, results
strongly show the efficacy of ω-3 FAs on depression. In addition, when looking at studies
examining ω-3 FAs and anxiety, there are diverse measures of anxiety utilized ranging from
general anxiety symptoms to more specific anxiety (e.g., test anxiety). It is important to
accurately assess the type of psychological symptoms since different symptoms may modify the
effectiveness of ω-3 FAs, and thus would determine the specific patient populations that ω-3 FAs
would be recommended for.
Current Project Aims and Hypotheses
Although there are many advances in modern medicine, the rate of psychiatric illness
continues to rise. Expanding research efforts to incorporate additional factors that may improve
psychological health, such as diet, can potentially enhance the development, management and
prevention of anxiety and depression. Many studies have examined the relationship between ω-3
FAs and depression and anxiety demonstrating a positive impact on psychological symptoms.
Yet few studies have examined the potential mechanisms underlying the relationship between ω3 FAs and depression and anxiety.
The present study aims to explore the potential mechanisms underlying the relationship
between ω-3 FAs, and stress, anxiety and depression symptoms, with the hypothesized
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mechanisms being inflammation and the gut microbiome. Many of the variables outlined have
been examined separately in animal and human samples, however, no one study has examined
the associations between ω-3 intake, gut microbiota functioning, inflammatory markers, and
stress, anxiety and depression outcomes in a human sample. Given that research has established
that diet has a considerable impact on both physical and mental health, the present study aims to
expand the literature by understanding the ways in which these relationships occur. Additionally,
since this is the first study examining these relationships, paired with evidence that males and
females exhibit differences in ω-3 levels (Kitson, Stroud, & Stark, 2010) and presentation of gut
bacteria (Jašarević, Morrison, & Bale, 2016) due to differences in sex hormones; we will recruit
an all female sample. Elucidating these relationships will shed light onto how dietary intake can
influence our biological functioning and subsequently, mental health conditions. This
understanding will, in turn, be able to shape the way we understand how psychological
conditions develop and can help influence the prevention and treatment of anxiety and
depression.
The specific aims for the proposed study are two-fold: 1) To examine the crosssectional relationship between ω-3 FAs, gut microbiome bacteria and inflammatory
markers, and stress, anxiety and depressive symptoms. It is hypothesized that lower ω-3
intake will be associated with greater stress, anxiety, and depression symptoms. Lower ω-3
intake will be associated with deceased levels of Lactobacillus and Bifidobacterium and
increased inflammation (TNF-α, IL-6, IL-8, IL-1β). Deceased levels of Lactobacillus and
Bifidobacterium and increased inflammation will be associated with greater stress, anxiety, and
depression symptoms. 2) To examine if the gut microbiome and inflammatory markers
mediate the relationship between ω-3 intake and stress, anxiety and depressive symptoms.
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It is hypothesized that ω-3 intake will have an indirect association with anxiety and depressive
symptoms through the gut microbiome (Lactobacillus and Bifidobacterium) and inflammatory
markers (TNF-α, IL-6, IL-8, IL-1β) (see Figure 5).
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CHAPTER II: METHODOLOGY
Participant Characteristics
Healthy adult females ages 18 and older and fluent in English were recruited to
participate in the present study (N = 79). Participants were students, faculty, and staff from
Brooklyn College or from the local community. Participants were excluded if they were
pregnant, have been diagnosed with an inflammatory or endocrine illness, engaged in heavy
alcohol use (more than two glasses of alcohol per day) or heavy smoking (more than eight
cigarettes per day), or have been in psychological or psychiatric treatment for less than 6 months.
Participant demographic information is presented in Table 1. Participants ages ranged 18
to 42 years old (M = 21.7, SD = 4.1), the sample was all female, and they identified their
ethnicity as primarily Black (25.3%), White (24.1%), and Hispanic/Latino (24.1%). The majority
of participants reported single status (89.9%) and one third were part of a household income less
than $25,000 (34.2%). More than half of the participants (68.4%) were born via vaginal birth as
compared to cesarean section (25.3%). Approximately one third of participants (32.9%) reported
they were fed both breast milk and formula as a baby, one fourth of participants (24.1%) reported
being breast-fed, and formula-fed (24.1%), and approximately one fifth of participants (17.7%)
were not sure. The majority of participants are not currently taking an oral contraceptive (87.3%)
and denied past use of an oral contraceptive (75.9%).
Descriptive statistics of self- report measures are presented in Table 2. Based on the
established clinical cutoff scores, 39.2% of participants (n = 31) reported no to minimal
depressive symptoms, 41.8% of participants (n = 33) reported mild depressive symptoms, 15.2%
of participants (n = 12) reported moderate depressive symptoms and 3.8% of participants (n = 3)
reported severe depressive symptoms.
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Individuals with past oral contraceptive use reported higher stress symptoms on the PSS
(M = 23.11, SD = 4.81, n = 19) compared to those who have not used oral contraceptives (M =
19.05, SD = 6.87, n = 60) (t = 2.86, df = 43.15, p = 0.006). No other significant differences were
noted on self-report measures as a function of ethnicity, marital status, income, method of birth
(e.g., vaginal or cesarean section), breast fed or formula fed, or current oral contraceptive use.
Participant’s average ω-3 index, DHA, EPA, and ALA fatty acid percentage values are
presented in Table 3. No significant differences were noted on the ω-3 index as a function of
marital status, income, method of birth, breast fed or formula fed, or current or past oral
contraceptive use. There was a significant effect of ethnicity on DHA percentage values (F
(5,73) = 6.82, p < 0.001) and ω-3 Index levels (F (5,73) = 6.02, p < 0.001). Post hoccomparisons using a Tukey HSD test showed that DHA values for Asian/Pacific Islander
participants (M = 3.49, SD = 0.66) was significantly higher compared to White (M = 2.23, SD =
0.56), Hispanic (M = 2.53, SD = 0.69), or Mixed ethnicity (M = 2.24, SD = 0.53) participants.
DHA levels were also significantly higher in Black participants (M = 2.90, SD = 0.67) compared
to White participants. Post-hoc comparisons revealed similar findings for ω-3 Index levels where
the mean was significantly higher for Asian/Pacific Islander participants (M = 5.97, SD = 1.09)
compared to White (M = 4.32, SD = 0.66), Hispanic (M = 4.70, SD = 0.91), or Mixed ethnicity
(M = 4.46, SD = 0.80) participants. Omega-3 Index levels were also significantly higher in Black
participants (M = 5.22, SD = 0.94) compared to White participants (M = 4.32, SD = 0.66). These
differences in ethnicity were unsurprising as the literature has demonstrated that individuals of
Asian descent exhibit higher levels of ω-3s than White individuals (Xiao et al., 2016). Similarly,
a prospective cohort study in the United States has shown that Black participants had higher ω-3
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FAs (Villegas, Takata, Murff, & Blot, 2016) than White participants or those identifying as
another ethnicity.
The mean concentration of each inflammatory marker (IL-1β, IL-6, IL-8, TNF-α) in
pictograms per milliliter (pg/mL) are presented in Table 3. No significant differences in
inflammatory markers were noted as a function of marital status, ethnicity, income, method of
birth, breast fed or formula fed, and current or past oral contraceptive use.
The average percentages of abundance of gut bacteria (Lactobacillus and
Bifidobacterium) are presented in Table 3. No significant differences were noted on gut bacteria
between ethnicity, marital status, income, method of birth, breast fed or formula fed, or current
or past contraceptive use. A significant effect of income level was noted on Lactobacillus (F
(6,60) = 2.50, p < 0.03). Post hoc-comparisons using Tukey HSD indicated that the participants
with a household income of $75,000-$99,999 (M = 5.42, SD = 9.09) has significantly higher
abundance of Lactobacillus compared to participants with a household income of less than
$25,000 (M = 0.68, SD = 1.46), $35,000-$49,999 (M = 0.04, SD = 0.08), and $50,000-$74,999
(M = 0.37, SD = 0.52). It is important to note that this difference in income level could be a type
I error given that the household income group of $75,000-$99,000 only has three participants.
Recruitment
Participants were recruited via flyer postings around the Brooklyn College campus. Study
information was disseminated via electronic mail to reach Brooklyn College students and faculty
members. We also used snowball sampling, where existing participants recruited future
participants, and online advertisement posting websites (e.g., Craig’s list). All participants who
express interest in participating in the study were briefly screened to determine study eligibility.
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Study Procedures
Once screened as eligible, participants were scheduled to come to Brooklyn College for
their assessment. Participants were emailed 24 hours prior to remind them of their appointment
and of the saliva collection instructions (e.g., do not drink alcohol or smoke 12 hours prior to the
appointment, and do not eat, drink caffeinated beverages, brush their teeth or use mouthwash one
hour prior to the appointment). After arriving to the lab, participants completed the informed
consent procedure with a research assistant. Next participants were asked about saliva-collectionspecific criteria. If the participant has complied, a saliva sample was taken to measure
inflammatory cytokines. Participants provided a minimum of 0.5ml and up to 2ml of a saliva
sample. Saliva samples were collected using passive drool, which means that participants were
asked to drool into a small tube, and used a straw to facilitate saliva collection. Once collected,
saliva samples were immediately placed into a freezer approximately -20 degrees Celsius until
they were ready to be analyzed.
Next, the dried blood spot sample was collected. Each participant had their sample
collected by a trained research assistant and materials used were from an individual sealed kit.
Participants were asked to wash their hands with warm water and hold them at their sides for 20
seconds to increase circulation to their fingers. A research assistant cleaned the participant’s
middle or ring finger with an alcohol swab and then used a sterile lancet positioned on the side of
the finger and pressed firmly until a click was heard and the needle was inserted. Blood was
collected on the finger and the finger was lightly squeezed to facilitate blood flow. The
participant's’ finger was pressed on the center of the sample collection card. This was repeated
until the entire collection circle was filled with blood. Afterwards pressure was applied to the
finger with a gauze pad and a bandage was applied. Once the blood spot had dried for 15-20
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minutes the collection card immediately placed into a freezer approximately -20 degrees Celsius
until they were ready to be analyzed.
Following the saliva and blood sample collection, participants completed the self-report
measures (e.g., demographic history, PSS, STAI, BDI) on a laptop in the research lab. After all
self-report measures were completed, the research assistant gave the participant a uBiome stool
sample kit with a unique ID number. Sampling was done privately in a bathroom on campus or
in their home. Collection of stool sample takes less than two minutes and is a noninvasive
procedure. Participants were instructed to swab their toilet paper, put the swab in a tube
provided, and shake the tube for one minute. Then, participants placed their sample in a pre-paid
return mailer. Once complete, the sample can be stored at room temperature for up to one month,
however, the participant was instructed to mail out the sample to uBiome by placing in a mailbox
promptly after collection. Any personal health information that participants provided are
protected by the uBiome privacy practices; uBiome is required by the Health Insurance
Portability and Accountability Act of 1996 (HIPAA) to keep all health information confidential.
Once instructions were discussed and understood participants were given $25 for their
participation signed a receipt acknowledging their payment.
Self-Report Measures
Demographic information collected included: age, gender, race, education level, past and
present geographic location, food allergies, dietary restrictions, specific amount of smoking and
alcohol use, whether the participant was born via cesarean section or via vaginal delivery,
whether the participant was breast fed or formula fed, and past or current treatment for anxiety.
Perceived Stress Scale (PSS): The PSS is a widely used instrument to assess perceived
stress over the past month (Cohen, Kamarck, & Mermelstein, 1994). The PSS is a 10-item
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measure assessing the degree in which particular areas in one’s life are perceived as stressful.
Items are rated on a 5-point Likert scale (0 = never, to 4 = very often). Total PSS scores are
calculated by reverse-coding four reverse-worded items and then summing across all scale items.
Total scores can range from 0-40, with higher scores reflecting higher perceived levels of stress.
The PSS demonstrates good reliability and validity (Siqueira Reis, Ferreira Hino, & Romélio
Rodriguez-Añez, 2010). The measure had good internal consistency in the present sample (α =
0.87) on the PSS.
State-Trait Anxiety Inventory (STAI): Anxiety was measured using the STAI
(Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1983). The STAI is a self-report measure that
assesses state and trait anxiety in patients. The inventory has 40 questions, 20 assessing state
anxiety or in a specific situation (STAI-S) and 20 assessing general trait anxiety or a stable
disposition (STAI-T). Items are rated on a four-point scale (1 = almost never, to 4 = almost
always) with higher scores indicating greater anxiety. The STAI has shown to be highly reliable
and valid (Vitasari, Wahab, Herawan, Othman, & Sinnadurai, 2011). The measure demonstrated
excellent reliability (α = 0.95) in the present sample.
Beck Depression Inventory (BDI): To assess depressive symptoms, the BDI was
administered (Beck, Ward, Mendelson, Mock, & Erbaugh, 1961). The BDI is a 21-item selfreport measure that assesses clinical severity of depressive symptoms. There are four possible
responses for each item ranging from 0-3, depending on intensity. Scores are calculated by
summing across the 21 items. Total depression scores are categorized as minimal (0–9), mild
(10–18), moderate (19–29) and severe depression (30–63). The BDI has been found to be a
reliable and valid measure (Reynolds & Gould, 1981). The BDI had high reliability (α = 0.87) in
the present sample.
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Omega-3 Index & Omega-3
Omega-3 FAs was measured via dried blood spot samples from a finger prick using the
Omega-3 Index Kit provided by and analyzed by Omega Quant Laboratories (OmegaQuant
Analytics, Sioux Falls, SD). An Omega-3 Index will be calculated which reflects the EPA and
DHA content of the red blood cells. This will be reported as a percentage of the total identified
fatty acids in the blood. In addition, a full blood fatty acid profile will be provided with 24
individual fatty acid values. This method has been previously used in assessing Omega-3 Index
in patients with depression (Baghai et al., 2011), U.S. servicemen (Johnston, Deuster, Harris,
MacRae, & Dretsch, 2013) and vegans (Sarter, Kelsey, Schwartz, & Harris, 2015).
Inflammatory Measurement
Proinflammatory biomarkers were assessed via salvia sample. Specific biomarkers that
were measured include TNF-α, IL-6, IL-8, IL-1β. Salvia was collected using passive drool and
analyzed by Salimetrics Laboratory using enzyme-linked immunosorbent assay (ELISA)
(Salimetrics, LLC, State College, Pennsylvania). In order to collect the most accurate assessment
of inflammatory markers, participants were instructed not to drink alcohol or smoke 12 hours
prior to testing. In addition, they were instructed not to eat, drink caffeinated beverages, brush
their teeth or use mouthwash one hour prior to testing. The results from each biomarker included
two reports from each participant and the average in pictograms per milliliter (pg/mL).
Gut Microbiome
Levels of gut bacteria, Lactobacillus and Bifidobacterium, were measured from
participants stool samples. Participants were given a uBiome stool sample kit and provided
instructions as to how to submit their stool sample. Participants used a sterile cotton swab to
transfer fecal matter into a vial containing a lysis and stabilization buffer that protects DNA
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during transportation. Each kit has a unique Kit ID associated with it and was assigned to a
participant. Therefore, the participant did not include any identifying information when mailing
out their fecal sample. Data from the stool sample was collected by uBiome and linked to a
research account created by the PI. Lactobacillus and Bifidobacterium levels of each participant
were displayed as a percentage of abundance compared to the general population to determine if
they are above or below average.
Statistical Analysis
Power analyses were conducted using G Power software (Faul, Erdfelder, Buchner, &
Lang, 2009). Statistical analysis was conducted in IBM SPSS Statistics Version 25. The goal was
to have 60 participants complete the current study. We estimated a 20% non-compliance rate
(e.g., not providing a stool sample), thus, we aimed to recruit a projected estimate of 80
participants to achieve our goal. A sensitivity power analysis was calculated based on a desired
power of .80 and the predetermined sample size (Faul, Erdfelder, Lang, & Buchner, 2007). For a
linear multiple regression with three predictors, based on 60 participants, α = 0.05, and a power
of .80, a medium effect size (f 2 = 0.19) will be able to be detected. Effect sizes can be classified
as small (f 2 = 0.02), medium (f 2 = 0.15), or large (f 2 = 0.35).
Aim 1: To investigate the cross-sectional associations between ω-3 FAs (EPA/DHA),
stress, anxiety and depressive symptoms (PSS, STAI, BDI), inflammatory markers (TNF-α, IL-6,
IL-10) and gut bacteria (Lactobacillus and Bifidobacterium), Pearson correlation analyses will be
conducted. A Bonferroni correction will be applied, diving alpha by the number of comparisons
being made, which is used when multiple comparisons occur simultaneously in the one analysis
to prevent Type I error. Pearson correlation coefficients can be classified as positive or negative,
and can range from a very weak relationship (r = 0.00-0.19), to a weak relationship (r = 0.20-
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0.39), to a moderate relationship (r = 0.40-0.69), to a strong relationship (r = 0.70-0.89), to a
very strong relationship (r = 0.90-1.00) (Cohen & Holiday, 1982). It is hypothesized there will
be a negative association between ω-3 intake and stress, anxiety and depressive symptoms (Aim
1A) given that previous research has found support for this relationship in both animal and
human subjects (Carrié et al., 2002; Ferraz et al., 2008; Jacka et al.2013; Raeder et al., 2007). It
is predicted there will also be a negative association between ω-3 intake and inflammation (Aim
1B). Studies have found decreased levels proinflammatory markers correlated to ω-3FA
supplementation (Wall, Ross, Fitzgerald, & Stanton, 2010). Furthermore, it is hypothesized there
will be a positive association between ω-3 intake and levels of Lactobacillus and
Bifidobacterium (Aim 1C) as studies have shown that ω-3 supplementation is related to
increased levels of these bacteria mice (Robertson et al., 2016) and supplementation of
Bifidobacterium was correlated to increased ALA concentration in human infants (Robertson et
al., 2016). We predict there will be a negative association between Lactobacillus and
Bifidobacterium and stress, anxiety and depressive symptoms (Aim 1D) since previous studies
have shown that supplementation of Lactobacillus was associated with decreased anxious and
depressive behavior in rats (Bravo et al., 2011) and decreased distress symptoms in humans
(Messaoudi et al., 2011). Lastly, inflammation is hypothesized to have a positive relationship
with stress, anxiety and depression symptoms (Aim 1E) as studies have demonstrated
inflammatory markers to be positively associated with anxiety and depressive disorders
(Khandaker, et al. 2016; Lindqvist et al., 2017).
Aim 2: To examine if the gut microbiome and inflammatory markers mediate the
relationship between ω-3 intake and stress, anxiety and depressive symptoms, we will utilize the
computational and modeling program PROCESS v.2.15 (Hayes 2013) to test both direct and
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indirect effects. PROCESS Model 6 was selected to test for serial mediation, where the predictor
is modeled to exert an effect on the outcome through two mediators linked in a causal chain
(Hayes, 2015). The bootstrapping resampling method was utilized, using 5000 bootstrap
samples, this nonparametric method estimates direct and indirect effects and 95% bias-corrected
confidence intervals and does not assume normality.
This study aims to investigate the direct and indirect effects of ω-3 FAs on the three
dependent variables of stress, anxiety, and depressive symptoms and the mediating role of gut
bacteria and inflammation. For the present study, stress, anxiety, and depressive scores were
entered as the outcome variable, measures of ω-3 FAs as the predictor variables, and gut bacteria
and inflammatory markers as the mediators. To test all combinations of serial mediation, each
possible combination will be independently run. With four outcome variables (stress, traitanxiety, state-anxiety, depression), four predictor variables (ω-3 Index, DHA, EPA, ALA), and
six mediator variables (Lactobacillus, Bifidobacterium, and TNF-α, IL-6, IL-8, IL-1b) there are
128 possible mediation analyses (32 separate analyses for each outcome variable).
The first set of analyses will examine the direct and indirect effects of ω-3 FAs, the
predictor variable, on stress symptoms, through the two mediators, gut bacteria and inflammation
(Aim 2A) (Figure 2). The second set of analyses will examine the direct and indirect effects of
ω-3 FAs on anxiety symptoms, through the mediator’s gut bacteria and inflammation (Aim 2B)
(Figure 3). Lastly, the third set of analyses will examine the direct and indirect effects of ω-3
FAs on depressive symptoms, through the mediator’s gut bacteria and inflammation (Aim 2C)
(Figure 4).
Specifically the following relationships will be analyzed in mediation analysis: 1) the
direct relationship between ω-3 and stress, anxiety, and depression symptoms, 2) the direct
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relationship between ω-3 and gut bacteria, 3) the direct relationship between ω-3 and
inflammation, 4) the direct relationship between gut bacteria and inflammation, 5) the direct
relationship between gut bacteria and stress, anxiety, and depression symptoms, 6) the direct
relationship between inflammation and stress, anxiety, and depression symptoms, 7) the indirect
relationship between ω-3 and stress, anxiety, and depression symptoms through gut bacteria, 8)
the indirect relationship between ω-3 and stress, anxiety, and depression symptoms through
inflammation, and 9) the indirect effect of ω-3 and stress, anxiety, and depression symptoms
through both gut bacteria and inflammation. We will test whether any demographic variables
(e.g., race, marital status, income) are significantly related to any outcome variables and if so,
they will be entered into the model as covariates given that these relationships have not been
previously examined and these affect dietary intake (Al-Numair, Lewis & Evans, 2005; Darmon
& Drewnowski, 2008; Franco et al., 2009).
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CHAPTER III: RESULTS
Normality
The distributions of study variables were inspected for normality using visual inspection
and normality tests of skewness, kurtosis, and Shapiro-Wilk values (Appendix X). Normality
was defined as a skew and kurtosis z-score between -2 and 2 (Bulmer, 1979). Report of
depression symptoms, state-anxiety symptoms, trait-anxiety symptoms, inflammation data, ω-3
data, and gut bacteria data were all positively skewed. Both square root and logarithmic
transformations were conducted (Appendix Y), as these two transformation methods are
recommended for positively skewed data (Howell, 2007; Tabachnick, & Fidell, 2007). For the
next section (Aim 1), the nonparametric Spearman rank correlation coefficient was used with
non-transformed data to examine associations among variable because the data did not meet
normality assumptions. Once log transformations were conducted, Pearson correlations were
utilized to examine study variable relationships. The results are presented for both analyses for
Aim 1.
Aim 1 (5 hypotheses): Bivariate relationships between ω-3 FAs, gut microbiome bacteria,
inflammatory markers, and psychological self-report measures.
For the first hypothesis, the association between ω-3 intake and psychological self-report
measures (Aim 1A) was examined. There was a negative association between ω-3 index and
trait-anxiety symptoms (ρ (77) = -0.29, p = 0.01) as well as DHA levels and trait-anxiety
symptoms (ρ (77) = -0.30, p = 0.01). Contrary to our hypotheses, there was no significant
relationships between ω-3 intake and any other psychological measure (see Table 4).
As anticipated, there was a significant negative relationship between ω-3 index and
inflammatory marker IL-1β (ρ (77) = -0.26, p = 0.02) and between DHA and IL-1β (ρ (77) = -
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0.24, p = 0.03). However, there was no significant relationship between ω-3 intake and other
inflammatory markers (Aim 1B) (see Table 5). Furthermore, gut bacteria levels were not
significantly associated with ω-3 intake (Aim 1C) (see Table 6) or psychological self-report
measures (Aim 1D) (see Table 7). We found a weak positive association between depression
symptoms and the inflammatory marker IL-1β (ρ (77) = 0.26, p = 0.02) (AIM 1E) (see Table 8).
No other significant relationships were noted between inflammatory markers and psychological
self-report measures.
Log-transformed Correlational Results
In addition to running Spearman’s correlation, the original data were log transformed to
allow for the use of Pearson’s correlation to examine study variable relationships. Results using
Pearson correlations on transformed data were similar to findings for Aim 1A using Spearman
correlations; there was a negative relationship between trait-anxiety symptoms and both ω-3
index (r (77) = -0.28, p = 0.01) and DHA levels (r (77) = -0.30, p = 0.01). There was one
additional finding for Aim 1A, there was a negative association between depression symptoms
and ω-3 index (r (77) = -0.24, p = 0.03) and DHA levels (r (77) = -0.24, p = 0.03). For the
remainder of the hypothesized associations, all results were non-significant. Overall, Pearson
correlation results demonstrate a similar negative relationship between trait-anxiety and both ω-3
index and DHA. One new association was found between ω-3 index and depressive symptoms.
There were three associations that were found in the Spearman’s correlation analyses were not
found when conducting the Pearson’s correlations in that IL-1β was not associated with ω-3
index, DHA or depressive symptoms.
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Post-hoc Analysis
As a post-hoc analysis, we examined the relationship between gut bacteria and
inflammation which are the proposed mediating variables. No significant relationships were
noted between gut bacteria and inflammatory markers (Table 9) using Spearman rank correlation
or the Pearson correlation after log-transformation.

Aim 2: Serial mediation to test if gut bacteria and inflammatory markers mediate the
relationship between ω-3 intake and psychological self-report measures
Serial mediation models assessed whether gut bacteria and inflammatory markers
mediated the relationship between ω-3 intake levels and psychological symptoms. Specifically,
there are four outcome variables for psychological symptoms (stress, trait-anxiety, state-anxiety,
depression), four predictor variables of ω-3 intake (ω-3 Index, DHA, EPA, ALA), and six
mediator variables of gut bacteria and inflammatory markers (Lactobacillus, Bifidobacterium,
and TNF-α, IL-6, IL-8, IL-1β). Each possible combination was independently conducted,
resulting in 32 analyses for each outcome variable. Mediation results are separated by outcome
variables, first stress symptoms, next anxiety symptoms including trait- and state-anxiety, and
lastly depression symptoms. Across all 128 serial mediation analyses conducted, no mediation
was noted. However, several significant direct effects were detected (see Figure 5 for conceptual
model and key for direct effects). The findings for each predictor and outcome will be listed
below, regression coefficients reported are unstandardized.
Serial mediation analyses for stress symptoms (Aim 2A).
Omega-3 Index (predictor) and PSS. Across the eight models assessing the effect of the
ω-3 index on stress symptoms, three path coefficients were statistically significant (see Table
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10). IL-1β was positively associated with stress symptoms in the model with Lactobacillus (b =
0.01, t(63) = 2.33, p = 0.02) and in the model with Bifidobacterium (b = 0.01, t(63) = 2.46, p =
0.02). In addition, greater abundance of Lactobacillus significantly predicted higher levels of
inflammatory marker IL-8 (b = 57.96, t(64) = 2.50, p = 0.02).
DHA (predictor) and PSS. Similar results were found in the models assessing DHA on
stress symptoms (See Table 11). Higher levels of IL-1β predicted increased stress symptoms
when Lactobacillus was a mediator (b = 0.01, t(63) = 2.29, p = 0.03) and when Bifidobacterium
was a mediator (b = 0.01, t(63) = 2.44, p = 0.02). Furthermore, Lactobacillus was positively
associated with inflammatory marker IL-8 (b = 59.15, t(64) = 2.56, p = 0.01).
EPA (predictor) and PSS. With EPA as the predictor, seven path coefficients were
statistically significant (see Table 12). Inflammation was positively associated with stress
symptoms in four models. IL-1β significantly predicted stress symptoms when Lactobacillus was
a mediator (b = 0.01, t(63) = 2.49, p = 0.02) and when Bifidobacterium was a mediator (b = 0.01,
t(63) = 2.61, p = 0.01). Additionally, inflammatory marker IL-6 significantly predicted stress
symptoms in the models with Lactobacillus (b = 0.24, t(63) = 2.02, p = 0.05) and with
Bifidobacterium (b = 0.24, t(63) = 2.06, p = 0.04). Lactobacillus was positively associated with
inflammatory marker IL-8 (b = 57.17, t(64) = 2.41, p = 0.02). In two models, higher levels of
EPA predicted greater levels of inflammatory marker IL-6 when Lactobacillus was a mediator (b
= 8.27, t(64) = 2.12, p = 0.04) and when Bifidobacterium was a mediator (b = 7.77, t(64) = 1.98,
p = 0.05).
ALA (predictor) and PSS. Serial mediation results with ALA as the predictor were
similar to the results examining ω-3 index and DHA as the predictor (see Table 13). IL-1β was
positively associated with stress symptoms in the model with Lactobacillus (b = 0.01, t(63) =
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2.59, p = 0.01) and with Bifidobacterium (b = 0.01, t(63) = 2.72, p = 0.01). Furthermore
Lactobacillus significantly predicted IL-8 (b = 56.78, t(64) = 2.41, p = 0.02).
Post-hoc Analysis for PSS. Given that participants with past oral contraceptive use
reported higher stress symptoms compared to participants without past oral contraceptive use,
serial mediation models for the PSS were recomputed with past oral contraceptive use as a
covariate.
Omega-3 (predictor) and PSS with Covariate. Two of the three path coefficients
remained significant when adding past oral contraceptive use in the model, IL-1β was positively
associated with stress symptoms in the model with Bifidobacterium (b = 0.01, t(62) = 2.11, p =
0.04) and greater abundance of Lactobacillus significantly predicted higher levels of
inflammatory marker IL-8 (b = 56.56, t(63) = 2.40, p = 0.02). Inflammatory marker IL-1β was
no longer associated with stress symptoms in the model with Lactobacillus. In addition,
participants with past oral contraceptive use was associated with higher reported stress symptoms
across five of the eight models assessing ω-3 index on stress symptoms.
DHA (predictor) and PSS with Covariate. Results were comparable for the models
assessing DHA on stress symptoms. Two of the three path coefficients remained significant
when adding past oral contraceptive use in the model, IL-1β was positively associated with stress
symptoms in the model with Bifidobacterium (b = 0.01, t(62) = 2.09, p = 0.04) and greater
abundance of Lactobacillus significantly predicted higher levels of inflammatory marker IL-8 (b
= 57.71, t(63) = 2.45, p = 0.02). Similarly, inflammatory marker IL-1β was no longer
significantly associated with stress symptoms in the model with gut bacteria Lactobacillus. Past
oral contraceptive use positively predicted stress symptoms in four of the eight models analyzed.
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EPA (predictor) and PSS with Covariate. With EPA as the predictor, all seven path
coefficients remained to be statistically significant with past oral contraceptive use was entered
as a covariate. IL-1β continued to significantly predict stress symptoms when Lactobacillus was
a mediator (b = 0.01, t(62) = 2.07, p = 0.04) and when Bifidobacterium was a mediator (b = 0.01,
t(62) = 2.24, p = 0.03). Additionally, inflammatory marker IL-6 continued to significantly
predict stress symptoms in the models with Lactobacillus (b = 0.24, t(62) = 2.15, p = 0.04) and
with Bifidobacterium (b = 0.25, t(62) = 2.21, p = 0.03). Lactobacillus remained positively
associated with inflammatory marker IL-8 (b = 56.02, t(63) = 2.32, p = 0.02). In two models,
greater levels of EPA predicted higher levels of IL-6 when Lactobacillus was a mediator (b =
8.23, t(63) = 2.10, p = 0.04) and when Bifidobacterium was a mediator (b = 7.73, t(63) = 1.96, p
= 0.05). In addition to past oral contraceptive use being associated with increased stress
symptoms across all eight models, it was noted that past oral contraceptive use predicted
inflammatory marker IL-1β when Lactobacillus was a mediator (b = 137.29, t(63) = 1.97, p =
0.05).
ALA (predictor) and PSS with Covariate. Serial mediation analyses with ALA as the
predictor and past oral contraceptive use as a covariate led to the same three significant path
coefficients. IL-1β was positively associated with stress symptoms in the model with
Lactobacillus (b = 0.01, t(62) = 2.15, p = 0.04) and with Bifidobacterium (b = 0.01, t(62) = 2.32,
p = 0.02). Furthermore, Lactobacillus significantly predicted IL-8 (b = 56.00, t(63) = 2.34, p =
0.02). Additionally, past oral contraceptive use being associated with increased stress symptoms
across six of the eight models, and past oral contraceptive use predicted inflammatory marker IL1β when Lactobacillus was a mediator (b = 149.47, t(63) = 1.83, p = 0.04).

36
Summary for PSS. Four ω-3FA variables (ω-3-index, DHA, EPA, ALA) were tested as
predictors of stress symptoms (PSS) in a total of 32 serial mediation models (eight per predictor).
Across these models, ω-3FAs did not predict stress symptoms. However, several consistent
patterns emerged; higher levels of IL-1β predicted more reported stress symptoms and greater
abundance of the gut bacteria Lactobacillus significantly predicted higher levels of the
inflammatory marker IL-8. In the models with EPA as the predictor, EPA was positively
associated with IL-6 and IL-6 was positively associated with stress symptoms, however there
was not a significant indirect effect of IL-6 on the relationship between EPA and stress
symptoms. Furthermore, when past oral contraceptive use was entered as a covariate, past oral
contraceptive use predicted higher levels of reported stress symptoms across 23 of the 32 serial
mediation models. Lastly, there was a positive association between past oral contraceptive use
and inflammatory marker IL-1β in two models.

Serial mediation analyses for trait-anxiety symptoms (Aim 2B).
Omega-3 Index (predictor) and STAI-Trait. The direct effect of ω-3 levels on traitanxiety symptoms, without the influence of the mediators, was significant (see Table 14). The
total effect of ω-3 levels on trait-anxiety symptoms was significant (b = –3.62, t(65) = –2.73, p =
0.01), which is the sum of the direct and indirect effects of the model. Omega-3 index predicted
less trait-anxiety symptoms. One path coefficient was noted to be significant, Lactobacillus was
positively associated with inflammatory marker IL-8 (b = 57.96, t(64) = 2.50, p = 0.02).
DHA (predictor) and STAI-Trait. With DHA as the predictor, results were similar to ω-3
index results described above. The total effect of DHA on trait-anxiety symptoms was significant
(b = –4.87, t(65) = –2.69, p = 0.01), as well as a significant direct effect of DHA on trait-anxiety
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symptoms across all eight models (see Table 15). In addition, greater abundance of Lactobacillus
predicted higher levels of inflammatory marker IL-8 (d) (b = 59.15, t(64) = 2.56, p = 0.01).
EPA (predictor) and STAI-Trait. With EPA as the predictor, three path coefficients were
statistically significant (see Table 16). In two models, higher levels of EPA predicted higher
levels of the inflammatory marker IL-6, when Lactobacillus was entered as a mediator (b = 8.27,
t(64) = 2.12, p = 0.04) as well as when Bifidobacterium was entered as a mediator (b = 7.77,
t(64) = 1.98, p = 0.05). Additionally, Lactobacillus was positively associated with inflammatory
marker IL-8 (d) (b = 57.17, t(64) = 2.41, p = 0.02).
ALA (predictor) and STAI-Trait. Greater abundance of Lactobacillus predicted higher
levels of inflammatory marker IL-8 (b = 56.78, t(64) = 2.41, p = 0.02) when ALA was the
predictor (see Table 17).
Omega-3/DHA/EPA/ALA (predictor) and STAI-State. All serial mediation results for
the state-anxiety outcome demonstrated the same significant path coefficients as the trait-anxiety
results with the exception of the direct and total effects which were not significant. Specifically,
greater abundance of Lactobacillus was positively associated with inflammatory marker IL-8
when ω-3 was the predictor (b = 57.96, t(64) = 2.50, p = 0.02), when DHA was the predictor (b =
59.15, t(64) = 2.56, p = 0.01), when EPA was the predictor (b = 57.17, t(64) = 2.41, p = 0.02)
and when ALA was the predictor (b = 56.78, t(64) = 2.41, p = 0.02). Additionally, higher levels
of EPA predicted higher levels of the inflammatory marker IL-6, when Lactobacillus was entered
as a mediator (b = 8.27, t(64) = 2.12, p = 0.04) as well as when Bifidobacterium was entered as a
mediator (b = 7.77, t(64) = 1.98, p = 0.05).
Summary for STAI-Trait and STAI-State. Taken together, across the 64 serial mediation
models testing ω-3FA variables (ω-3-index, DHA, EPA, ALA) as predictors of trait- and state-
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anxiety symptoms (STAI-Trait and STAI-State) there was a direct and total effect of ω-3 index and
DHA predicting less trait-anxiety symptoms but not state-anxiety symptoms. It was consistently
found that greater abundance of Lactobacillus predicted higher levels of inflammatory marker
IL-8 and higher levels of EPA predicted greater levels of IL-6 across all serial mediation models
with trait- and state-anxiety symptoms as the outcome.

Serial mediation analyses for depression symptoms (Aim 2C).
Omega-3 Index (predictor) and BDI. A significant direct effect of ω-3 index on
depression symptoms was detected in five of the eight models (see Table 18), in that ω-3 index
predicted lower depression symptoms without the influence of the mediators. In addition, there
was a significant total effect of the model (b = –1.87, t(65) = –2.10, p = 0.04), taking into
account the direct and indirect effects of the model. Lastly, greater abundance of Lactobacillus
significantly predicted higher levels of the inflammatory marker IL-8 (b = 57.96, t(64) = 2.50, p
= 0.02).
DHA (predictor) and BDI. Two models were noted to show a significant direct effect of
DHA on depression symptoms (see Table 19), where DHA predicted less depression symptoms,
without taking into account the mediators. The total effect of DHA on depression symptoms was
significant (b = –2.40, t(65) = –1.97, p = 0.05), taking the sum of the direct and indirect effects of
the model. Additionally, one path coefficient was noted to be statistically significant in that
greater Lactobacillus abundance significantly predicted higher levels of IL-8 (b = 59.15, t(64) =
2.56, p = 0.01).
EPA (predictor) and BDI. With EPA as the predictor, three path coefficients were
statistically significant (see Table 20), similar to the results for trait-anxiety symptoms. In two
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models, higher levels of EPA predicted higher levels of the inflammatory marker IL-6, once
when Lactobacillus was a mediator (b = 8.27, t(64) = 2.12, p = 0.04) and when Bifidobacterium
was a mediator (b = 7.77, t(64) = 1.98, p = 0.05). In addition, Lactobacillus significantly
predicted higher levels of IL-8 (b = 57.17, t(64) = 2.41, p = 0.02).
ALA (predictor) and BDI. Only one path coefficient was significant (see Table 21) with
ALA as the predictor; Lactobacillus was positively associated with inflammatory marker IL-8 (b
= 56.78, t(64) = 2.41, p = 0.02).
Summary for BDI. Four ω-3FA variables (ω-3-index, DHA, EPA, ALA) were tested as
predictors of depressive symptoms (BDI) in a total of 32 serial mediation models. Across all
models, there was a significant total effect of ω-3 index and DHA predicting depressive
symptoms. For five models when ω-3 index was the predictor, and two models when DHA was
the predictor, there was a negative association with depression symptoms. There were some
consistencies in the findings, specifically, when Lactobacillus and inflammatory markers IL-6 or
TNF-α were mediators, a direct effect was noted. Collectively, across all 32 serial mediation
models with depression symptoms as the outcome, Lactobacillus significantly predicted higher
levels of inflammatory marker IL-8 and EPA significantly predicted higher levels of
inflammatory marker IL-6.

Global Summary of Mediation Analyses.
Within the 128 serial mediation models conducted, several patterns were detected. When
examining anxiety symptoms, there was a direct and total effect of ω-3 index and DHA
predicting less trait-anxiety symptoms, however, there was no significant effect for state-anxiety
symptoms. A significant total effect of ω-3 index and DHA on depression symptoms was noted
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where ω-3 index and DHA predicted fewer depression symptoms. Gut bacteria and inflammation
were not found to mediate the relationship between ω-3 intake and stress, anxiety, or depression
symptoms. Consistently across all models, greater abundance of the gut bacteria Lactobacillus
predicted higher levels of inflammatory marker IL-8 and EPA significantly predicted higher
levels of inflammatory marker IL-6. Furthermore, inflammatory markers IL-1β and IL-6 were
found to significantly predict more stress symptoms.
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CHAPTER IV: DISCUSSION
The impact of nutrition on psychological health and cognitive functioning is a growing
topic of interest among researchers (Gomez-Pinilla, 2008). As mental health disorders continue
to rise globally, there is promising research supporting the importance of diet as a favorable
therapeutic option for managing psychological well-being, specifically ω-3 FAs. It has been well
established that ω-3 FAs are necessary for healthy mammalian central nervous system
development (Innis, 1991; Perica & Delaš, 2011), and more recently have been recognized to
play a favorable role on mental health symptoms (Golding et al., 2009; Ross, 2009).
With increasing interest in understanding the impact of ω-3 FAs on mental health
outcomes, research has begun to examine the underlying mechanisms that may explain this
relationship (Polokowski, Shakil, Carmichael, & Reigada, 2018). Much of the research
conducted to date involve animal subjects with a great amount of heterogeneity in results. Two
potential mediators based on the literature explaining the relationship between ω-3 FAs and
mental health symptoms are the inflammatory response and gut bacteria (Kaplan, Rucklidge,
Romijn, & McLeod, 2015). Specifically, it has been hypothesized that a poor-quality diet may
promote alteration in the gut microbiome, leading to an immune response of increased levels of
inflammatory markers, subsequently leading to depression (Berk et al., 2013). We contributed to
this innovative and burgeoning field of research by examining the relationship between nutrition
(along with its potential biological effect on gut bacteria and inflammation) with mental health
outcomes.
This study examined the effect of ω-3 FAs directly and indirectly on mental health
symptoms. The current study aimed to gain a better understanding of the ways in which ω-3 FAs,
and potential mediators (e.g., gut bacteria, inflammation), are related to mental health outcomes
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among a sample of healthy human subjects. We hypothesized a full mediation model such that
ω-3 FAs influence the gut microbiome by increasing healthy gut bacteria and consequently
reducing inflammation, resulting in decreased stress, anxiety, and depressive symptoms.
The first aim of this study was to examine the cross-sectional relationships between ω-3
FAs, gut microbiome bacteria, inflammation, and stress, anxiety and depressive symptoms.
Several significant correlations were detected across variables and are discussed below. The
second aim of the study was to examine whether specific gut bacteria and inflammatory markers
mediate the relationship between ω-3 intake and psychological outcomes. Given there are four
outcome variables (stress, trait-anxiety, state-anxiety, depression), four predictor variables (ω-3
Index, DHA, EPA, ALA), and six mediator variables (Lactobacillus, Bifidobacterium, and TNFα, IL-6, IL-8, IL-1β), 128 mediation analyses were conducted. Overall, across all serial
mediation models, no mediation was detected. Thus, we did not find gut bacteria or
inflammation to mediate the relationship between ω-3 FAs and stress, anxiety, or depression
symptoms. However, several significant direct effects were noted within the models and are
described below.
Omega-3 FAs and Mental Health Outcomes
One key finding from the present study is that ω-3 index and DHA were negatively
associated with trait-anxiety and depressive symptoms. That is, for participants with greater
amounts of ω-3 index or DHA, fewer depression and trait-anxiety symptoms were reported.
Direct effects among these variables were also replicated in the mediation analyses. Our findings
partially support our hypothesis that there would be a negative relationship between ω-3 FAs and
stress, anxiety, and depressive symptoms. No relationships were noted between EPA or ALA and
stress, anxiety, and depressive symptoms.
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It is well established in the literature that higher levels of ω-3 FAs are associated with
less depressive symptoms (Golding et al., 2009; Raeder et al., 2007) and more recently research
has reported a similar association with anxiety disorders (Jacka et al., 2013), and comorbid
depression and anxiety disorders (Thesing, Bot, Milaneschi, Giltay, & Penninx, 2017).
Additional, support for the link between ω-3 FAs and mental health has also been tested using
RCT designs. One RCT with 432 adult outpatients experiencing a major depressive episode
demonstrated that participants taking ω-3 FAs showed reduced depressive symptoms as
compared to those taking a placebo (Lesperance, 2011). Another RCT examining children with
major depressive disorder who were administered a ω-3 supplement or placebo (Nemets, Apter,
Bracha, & Belmaker 2006) found that ω-3 supplement demonstrated therapeutic benefits in
depression based on both clinician and patient report. Furthermore, a RCT examining substance
users found that ω-3 supplementation improved anxiety symptoms compared to those in a
placebo condition (Buydens-Branchey, Branchey, & Hibbeln, 2008). Similarly, a systematic
review and meta-analysis of ω-3 FAs and anxiety found much heterogeneity, yet an overall
reduction in anxiety symptoms with those participants receiving ω-3 FA supplements compared
to controls (Su, et al., 2018). The findings of this study further contribute to this growing body of
research, supporting a negative association between ω-3 FAs and depression and anxiety
symptoms.
While this study did find that ω-3 index and DHA levels were associated with fewer
depression and trait-anxiety symptoms, no relationship was noted with the other psychological
outcomes (state-anxiety or stress symptoms). Trait-anxiety and depression symptoms assessed in
this study likely reflect a more stable, prominent, and consistent pattern of mood in participants
which was negatively associated with ω-3 index and DHA levels. Furthermore, depression is
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highly comorbid with anxiety disorders (Richter et al., 1998) which may explain the similar
findings in trait-anxiety and depression symptoms. In comparison, state-anxiety can be described
as an anxiety response to a specific stressor where a circumstance is perceived as threatening
(Barnes, Harp, & Jung, 2002). Similar to state-anxiety, the PSS assessed stress symptoms over
the past month (Cohen, Kamarck, & Mermelstein, 1994). The PSS and state-anxiety likely
overlap as they are designed to assess perceived feelings of stress or anxiety in a more fluid
context.
Others have also noted that more persistent and stable psychological symptoms are
related to diet compared to more temporary states of anxiety or stress (Grosso et al. 2014a). The
review paper conducted by Su and colleagues (2018) examining anxiety symptoms after ω-3 FA
supplementation, supports our study findings as they note that subgroups with a clinical
diagnosis, compared to those without, demonstrated a greater reduction in anxiety symptoms.
Accordingly, diet may be a more beneficial intervention for populations with clinical symptoms
rather than general populations. Clinical trials have shown that individuals with clinical
diagnoses of major depressive disorder, anxiety, and early phase psychosis have benefitted from
ω-3 FA supplementation (Chen, Chibnall, & Nasrallah, 2015; Grosso et al. 2014a; Su et al.,
2018). In a cohort of French adults followed for two years, subjects whom consumed fatty fish or
whom had an intake of ω-3 FA higher than 0.10% of energy intake demonstrated less risk of a
depressive episode and of a recurrent depressive episode (Astorg, et al., 2008). These findings
suggest that it may be more valuable to conduct future investigations of ω-3 FA supplementation
with samples with more chronic symptomatology compared to individuals with sub-clinical
mental health symptoms.
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In addition, the current study found that the type of ω-3 FA mattered. Results showed
that DHA predicted less depression and trait-anxiety symptoms while EPA and ALA were not
associated psychological outcomes. There has been some evidence supporting the negative
relationship between DHA and depression symptoms in healthy adults (Mamalakis, Tornaritis, &
Kafatos, 2002; Sarri, Linardakis, Tzanakis, & Kafatos, 2008). Specifically, it has been shown
that higher DHA levels in mothers’ breast milk predicted lower rates of postpartum depression
(Hibbeln, 2002). In a postmortem study, patients with major depressive disorder had
significantly less DHA in the orbitofrontal cortex compared to controls (McNamara et al., 2007).
Furthermore, one case control study investigating 800 United States military personnel compared
to 800 controls, found that low levels of DHA was a significant risk factor for suicide, while
there was no association with EPA levels (Lewis et al., 2011). These findings highlight the value
of DHA. In particular, incorporating DHA via supplements or dietary sources may be a novel yet
significant intervention when treating individuals with severe psychological symptoms such as
major depression or suicidality.
One area that requires further examination is why our findings only showed an
association between DHA and depression and trait-anxiety symptoms, but not other types of ω-3
FA. Both DHA and EPA are found within the same food groups such as fish, shellfish, and algae
(Anderson & Ma, 2009) which indicates that differences in dietary sources of our participants are
an unlikely explanation. One possible explanation for the difference in ω-3 FA type and
psychological outcomes is that the process by which DHA and EPA metabolizes may be distinct
from one another. Indeed, researchers have not clearly identified the ways in which DHA is
metabolized. Across the literature, the majority of studies report DHA levels within the blood,
however, it is unknown whether DHA supplementation truly increases the level of DHA in the
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brain (Sublette, Ellis, Geant, & Mann, 2011). There seems to be varying mechanisms by which
DHA is transported to the brain and to the blood based on animal models which remain to be
unclear (Chouinard-Watkins, Lacombe, Metherel, Masoodi, & Bazinet, 2019). Furthermore, it
has been established that there is greater abundance of DHA in the brain compared to EPA,
however, it is unclear whether EPA metabolizes more quickly than DHA or if there is low EPA
uptake by the brain (Sublette, Ellis, Geant, & Mann, 2011; Hallahan et al., 2016). Research has
also demonstrated that DHA clears from plasma at a slower rate than EPA, with some evidence
showing that after 24 weeks of discontinuing ω-3 supplements, DHA levels did not reach
baseline levels (Arterburn, Hall, & Oken, 2006). Thus, DHA may be detected in red blood cells
for longer periods of time than EPA. In regards to the present study, we found support for DHA,
and not EPA, predicting less depression and trait-anxiety symptoms based on levels within whole
blood samples. This finding further supports the growing acknowledgement that there are
differences between EPA and DHA. When evaluating the literature examining EPA and DHA, it
is important to evaluate RCT’s and cross-sectional research independently. For instance, much of
the research trials administering EPA and DHA supplements to participants do not objectively
assess EPA and DHA in participants (Hallahan et al., 2016) and many of the cross-sectional
studies do not assess EPA and DHA intake via diet or supplements.
Given that the present study examines cross-sectional data, it is necessary to consider that
individuals with less anxiety and depression may make healthier food choices that results in
higher ω-3 FA intake rather than their diet affecting their mental health. For instance,
undergraduate students who reported increased stress while waiting for an exam grade
experienced increased tendency to eat compared to a control group (Macht, Haupt, & Ellgring,
2004). Furthermore, women who are in stressful situations tend to consume larger quantities of
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food compared to women in a low-stress condition (Habhab, Sheldon, & Loeb, 2008). Research
has also shown that foods higher in fat may reduce stress (Finger, Dinan, & Cryan, 2011;
Maniam & Morris, 2010). Careful consideration must be made when evaluating the relationship
between diet and mental health. There is likely a bidirectional relationship between affect and
food choice in which psychological state influence food choice and food consumed can influence
affect (Gibson, 2006).
Omega-3 FAs and Inflammation
Contrary to much of the literature and our hypothesis, lower ω-3 FA intake was not
associated with lower inflammatory markers. In general, there was no relationship between ω-3
FAs and inflammatory markers, with one exception, higher levels of EPA significantly predicted
greater levels of inflammatory marker IL-6. Some clinical trials administering ω-3 supplements
in medical populations (e.g., hypertriglyceridemia, obesity) have not found an effect of ω-3 FAs
on inflammation, which may be due to treatment duration or negative impacts on insulin
sensitivity which can increase inflammatory markers (Chan, Watts, Barrett, Beilin, & Mori,
2002; Skulas-Ray et al., 2011). However, our findings were unexpected given that ω-3 FA
supplementation has been widely shown to reduce inflammatory markers (Li, Huang, Zheng,
Wu, & Li, 2014; Wall, Ross, Fitzgerald, & Stanton, 2010). One study examining the impact of
EPA and DHA on inflammatory markers in adipocytes (cells storing fat) has shown that EPA
supplementation increased the concentration of IL-6 while DHA decreased the concentration of
IL-6 (Prostek, Gajewska, Kamola, & Balaninska, 2014). The authors posit that EPA and DHA
may have a different effect on the inflammatory process during various stages of cell maturation
which may explain why EPA has shown to potentially both reduce (Hao et al., 2010) and
increase inflammatory markers. Although, IL-6 is largely conceptualized as having pro-
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inflammatory properties, a couple of review articles (Hawkley, Bosch, Engeland, Cacioppo, &
Marucha, 2007; Woods, Vieira, & Keylock, 2009) note the anti-inflammatory nature of IL-6
which may be one possible explanation as to why EPA may be related to increased IL-6. It has
been found that IL-6 may inhibit the response of increased levels of IL-1β and TNF-α and play a
role in impeding the inflammatory response (Luheshi et al., 1997).
It is important to acknowledge that the method of inflammatory marker assessment was
via saliva. Salivary inflammatory markers have been shown to be sensitive to acute stress, even
collecting salivary samples at multiple time points at one laboratory visit can demonstrate
differences in levels of inflammation (Slavish, Graham-Engeland, Smyth, & Engeland, 2015). In
the present study, we attempted to control for experimental stress effects on inflammation by
collecting the saliva sample at the beginning of the lab visit; prior to the finger prick and the
administration of self-report measures to reduce the potential contribution of acute stress in
salivary measurement. Additionally, we also attempted to control for confounding inflammation
factors by excluding participants from our study who were diagnosed with an inflammatory or
endocrine illness, engaged in heavy alcohol use (more than two glasses of alcohol per day) or
heavy smoking (more than eight cigarettes per day). However, we did not control for the
waketime of participants. It has been shown that inflammatory markers may vary in salivary
samples based on time of the day a sample is provided (DeSantis et al., 2013). Lastly, oral health
status (e.g., gingivitis) may confound measures of salivary inflammation (Deinzer et al., 2004)
which was not assessed in our sample.
Inflammation and Mental Health Outcomes
We hypothesized that higher levels of inflammation would be associated with more
stress, anxiety, and depressive symptoms. This was partially supported as there was a positive
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relationship noted between inflammatory marker IL-1β and depression symptoms, and higher
levels of IL-1β and IL-6 significantly predict higher levels of stress symptoms. These findings
are consistent with a vast majority of the literature supporting the positive association between
inflammation and anxiety and depression (da Silva et al., 2017; Das, 2016; Dowlati et al., 2010;
Howren, Lamkin, Suls, 2009).
These findings add to the robust literature that inflammation is a critical component of
psychological health and should be targeted while treating patients with psychiatric illnesses. A
meta-analysis examining 14 RCTs with over 6,000 patients concluded that anti-inflammatory
treatment, specifically, nonsteroidal anti-inflammatory drugs, reduced depression symptoms and
did not increase patient’s risk for adverse events (Köhler, et al., 2014). Furthermore, there is
much evidence supporting that stress activates an inflammatory response via the hypothalamicpituitary-adrenal (HPA) axis which increases the expression of pro-inflammatory cytokines (Liu,
Wang, & Jiang, 2017). There is considerable evidence for the bidirectional relationship between
inflammation and depression, however it is likely that inflammation does not play a role in all
individuals with depression. Keicolt-Glaser and colleagues (2015) discuss the ways in which
multiple factors may contribute to a more robust inflammatory response (e.g., childhood
adversity, obesity, poor diet) in some individuals with depression and that targeting inflammation
in this population is essential for successful treatment.
Gut Bacteria and Inflammation
Although not hypothesized a priori, there was a small positive association between
Lactobacillus and IL-8 in that increased levels of Lactobacillus significantly predicted higher
levels of IL-8. This finding was unanticipated as Lactobacillus and Bifidobacterium were
hypothesized to have anti-inflammatory effects. If Lactobacillus does in fact promote
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inflammation, this would be an important finding to replicate given that this is classified as a
healthy bacteria and incorporated within many probiotic supplements. Similar to the present
finding, one study unexpectedly found that a high dose probiotic, including Lactobacillus did
increase IL-8 production (Zhang, Li, Caicedo, & Neu, 2005). The authors posit that the
overgrowth of some bacteria may potentially stimulate the inflammatory response. Thus, it is
possible that our sample had high levels of Lactobacillus which may have increased IL-8
production.
The research is novel when examining the relationship between gut bacteria and
inflammatory markers, with much of the studies conducted in animal models. A study examining
the effect of Lactobacillus in arthritic rats found that the rats that orally consumed Lactobacillus
experienced less joint inflammation than those rats who did not consume Lactobacillus (Baharav,
Mor, Halpern, & Weinberger, 2004). One study conducted in human subjects found that bacteria
Faecalibacterium prausnitzii, has been shown to demonstrate anti-inflammatory effects in
patients with Crohn’s disease, specifically blocking IL-8 production (Sokol et al., 2008).
Schirmer and colleagues (2016) have developed a database of predicted relationships between
gut bacteria and cytokine responses based on 500 healthy individuals. They note a negative
association between gut bacteria, Bifidobacterium adolescentis and TNF-α production. Due to
the inherent difficulty of studying the gut microbiome (e.g., multiple confounding variables),
clear relationships between gut bacteria and inflammatory markers are challenging to assess. As
research continues to develop and the techniques become more advanced, investigators will be
able to more accurately link specific gut bacteria to physiological and potentially psychological
outcomes.
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Strengths and Limitations
The present study is novel in that it is the first to study the associations between ω-3
intake, gut bacteria, inflammatory markers, and anxiety and depression outcomes in a human
sample. We found evidence that higher levels of ω-3 index and DHA were associated with lower
reported trait-anxiety symptoms, depressive symptoms, and lower concentrations of the
inflammatory marker IL-1β. We aimed to understand the ways in which ω-3 FAs impact mental
health outcomes by examining potential mediators. While gut bacteria and inflammation were
not found to mediate the relationship between ω-3 and psychological outcomes, this study can be
utilized as a framework and set the foundation for future research to examine these variables.
It has been recognized that one major source of heterogeneity in ω-3 FA research is the
influence of sex (Martins, 2009). In addition, many studies do not report the breakdown of
participant sex which is problematic. One strength of the current study is that, our sample was
comprised of all female participants. Overall, females have been found to have higher levels of
DHA compared to males, with the role of estrogen as one explanation (Kitson, Stroud, & Stark,
2010). Estrogen has been shown to cause higher concentrations of DHA in women than in men
(Giltay, Gooren, Toorians, Katan, & Zock, 2004). Kitson and colleagues (2010) posit that the
difference in DHA levels between males and females may be evolutionary; females have higher
concentrations of DHA in order to provide adequate DHA for fetal development. Thus,
examining the impact of ω-3 supplementation in men and women separately may help explain
some of the variance in findings.
Another strength of the current study was the utilization of dried blood spot samples to
assess ω-3 levels in our participants. This allows for an objective measure of ω-3 FAs rather than
calculating ω-3 intake based on subject self-report measures such as food frequency
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questionnaires. Based on our procedures of measuring ω-3 index via dried blood spots, we
obtained fatty acid values from the whole blood fatty acid profile, meaning both red blood cells
and plasma are collected by a finger prick. This method of assessing fatty acids via whole blood
spot collection has been found to be reliable, non-invasive, and more economical compared to
methods that require centrifugation (Gordon Bell et al., 2011). One study utilizing whole blood
fatty acid demonstrated increases in EPA and DHA levels six weeks after a dietary intervention
(Rise, Colombo, Ghezzi, Mauro, & Orlandini, 2011). Furthermore, four weeks post-intervention,
DHA levels continues to increase and EPA levels decreased slightly. These findings support the
utilization of whole blood fatty acid profiles as a method to assess ω-3 FA levels.
One strength, and also a potential study limitation, is the ethnic diversity of the sample.
The study was conducted in a metropolitan city in an urban university setting with a diverse
sample of approximately 25% Black, 25% White, 25% Hispanic/Latino, 15% Asian, and the
remaining participants identified as Mixed or Other. It is important to examine this demographic
feature when studying ω-3 FAs given that ethnicity does seem to impact accessibility to ω-3 FAs
or may influence genetic processing of ω-3 FAs. Certain cultures are exposed to higher
concentrations of ω-3 FAs such as Inuit/Eskimo and Japanese populations (Patel, Tracey,
Hughes, & Lip, 2010). Furthermore, some Europeans such as Italians tend to more efficiently
incorporate ω-3 FAs into their diet (Patel, Tracey, Hughes, & Lip, 2010). As described in our
results, Asian and Black participants were found to have higher levels of ω-3 index and DHA
than other races, however this was anticipated based on the literature (Villegas, Takata, Murff, &
Blot, 2016; Xiao et al., 2016).
A main limitation of this study is the methodological use of cross-sectional data which
prevents us from drawing robust conclusions since we are unable to determine the temporal order
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of the relationships analyzed. Based on the current state of the research, we hypothesized that ω3 FAs will influence the gut microbiome by increasing healthy gut bacteria and subsequently
reducing inflammatory cytokines, leading to decreased anxiety and depressive symptoms.
However, this hypothesized theoretical framework may not be accurate. One alternative
possibility is that anxiety and depressive symptoms may be increasing inflammation, leading to
reductions in healthy gut bacteria with ω-3 FAs moderating this relationship. For instance,
individuals with anxiety or depressive symptoms may demonstrate higher levels of inflammatory
markers and lower levels of healthy gut bacteria, however, consuming higher amounts of ω-3
FAs may serve as a protective factor against these negative effects.
Furthermore, the examination of ω-3 FAs alone may be limited. Researchers have posited
that it is important to examine both ω-3 and ω-6 FAs, as together they play a role in
inflammatory responses in the human body (Wall, Ross, Fitzgerald, & Stanton, 2010). However,
there is controversy within the literature regarding the utilization of the ω-6/ ω-3 ratio. Much
research has been done surrounding ω-3 FA and their anti-inflammatory properties however the
impact of ω-6 FAs is not as straightforward. Some ω-6 FAs have anti-inflammatory properties
(e.g.,dihomo-γ-linolenic acid) while others promote inflammation (e.g., arachidonic acid)
(Harris et al., 2009; Poorani, Bhatt, Dwarakanath, & Das, 2015). Over the past century, there has
been a drastic shift in dietary patterns, with a substantial increase in the amount of ω-6 FAs
consumed, due to the large amount of LA-enriched vegetable oils in the food supply, and
subsequently a deficiency of ω-3 FAs in the Western diet (Simopoulos, 2002). Some researchers
support the belief that this imbalance has resulted in a high ω-6 to ω-3 ratio of approximately
16:1, fostering the development of various diseases such as cardiovascular disease and note that
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the ideal ratio of ω-6 to ω-3 is 4:1 or 1:1 (Simopoulos, 2008). However, others claim that there is
no evidence that reducing ω-6 FA intake will prevent chronic illness (Harris, 2006).
Another weakness to this study lies within preliminary assessment and examination of
gut microbiome data in human subjects. There is more to be learned in the sampling and
processing of stool samples and recent research is attempting to create guidelines for collecting
stool samples to improve the validity of gut microbiome results (Gorzelak et al., 2015). There is
a limited understanding of the ways in which to interpret the gut microbiome as there are
countless numbers of microorganisms in the gastrointestinal tract. It is difficult to parse out the
specific impact of a particular bacteria given the all the factors that influence the microbiome.
Various environmental factors can influence the gut microbiome including antibiotics, diet, clean
environments, and stress (Kaplan, Rucklidge, Romijn, & McLeod, 2015). Some literature has
supported the idea that more diversity in the microbiome is healthier and having a less diverse
microbiome may be associated with chronic medical conditions (Liu, 2017). Thus, the gut
bacteria findings in the present study are preliminary and must be interpreted with caution.
A methodological limitation of the present study was the adherence of participants to
complete the uBiome gut kits. Participants completed majority of the study assessments in the
research lab, however, they subsequently were asked to submit a stool sample using the uBiome
kit after the lab visit. Of the 79 total participants, 67 completed and mailed in the uBiome kit
which is an 84.8% adherence rate. This resulted in missing gut bacteria data for a portion of our
sample. On average, our participants mailed out the uBiome kits within 4 days of receiving the
kit and completing baseline measures. In an attempt to increase adherence rates, research
assistants sent an email to participants the day after their assessment to verify their status on
submitting the kit. Additionally, since the uBiome kit was completed outside of the laboratory, it
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is unclear whether the participants correctly adhered to the instructions given to complete the
stool sample kit. There is little research published on adherence rates of gut bacteria kits
provided to study participants in a lab setting as this is a novel assessment in human participants.
To date, studies have collected fecal samples on human subjects via a research nurse collecting
directly from an adult participant’s home (Hill et al., 2016) or have been collected in infant
samples while they are admitted to the hospital (Williams et al., 2019). There has been some
research on adherence rates for self-collection methods in the cancer screening literature. When
offered to self-screen for cervical cancer at home with a kit, response rates were approximately
20-25% for women who received a kit in the mail (Gupta et al., 2018). Additional research is
needed surrounding adherence rates for self-collection procedures of stool samples by
participants outside of laboratory settings.
Another limitation was that our data did not meet the assumptions for normality. Due to
the non-normality of the data, Spearman’s correlation was utilized for the first aim of the study.
Spearman’s correlation is recommended when analyzing non-normal distributions while
maintaining Type 1 error rates (Bishara & Hittner, 2012). Additionally, as with any research
study using self-report data, there is a risk for biased responses. We administered self-report
measures of stress, anxiety, and depression symptoms. It is possible that participants were
inclined to respond to measures in a socially desirable manner (van de Mortel, 2008) and
conducting a structured interview to assess psychological symptoms could have potentially
improved the accuracy of mental health symptoms reported.
Future Directions
Based on the synthesis of the current research, a recommended next step would be to
conduct RCTs investigating various formulations of ω-3 supplementation within individuals with
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subthreshold and clinical levels of depression and anxiety. Prospective longitudinal studies such
as these will produce findings that can clearly be interpreted as causal, and will reveal the
magnitude of the specific types of ω-3 FAs on different types of symptomatology. Incorporating
repeated measures in clinical trials are a critical component to assess changes over time.
Moreover, prospective studies with a larger sample can test whether additional endogenous
variables moderate the relationship between ω-3 intake and psychological symptoms such as
race, gender, and biological markers (e.g., inflammatory markers, hormones). Future studies can
also improve the assessment of inflammation in particular by utilizing blood samples over saliva.
Measuring inflammatory markers via saliva has some benefits such as being non-invasive and
minimizing participant burden, however, there are methodological downfalls such as
inconsistency in collection methods and large variability in cortisol concentrations (Desai &
Mathews, 2014).
As mentioned in the Introduction, there are no established guidelines of ω-3 dosages to
improve mental health symptoms. Across studies, there is a large amount of variability in the
measurement and administration of ω-3 FAs. These methodological flaws seem to have an
impact on the results reported in the literature. For instance, a meta-analysis assessing the effects
of ω-3 FAs on major depressive disorder deemed the studies to be poor quality (e.g., nonblinding of participants to ω-3 supplement conditions, small sample sizes) and noted that there
was a large amount of heterogeneity among the studies reviewed (Appleton, Sallis, Perry, Ness,
& Churchill, 2015). Additionally, there is a large variety in the dosage, purity, and type of ω-3
FA supplements administered in clinical trials. As such, while conducting their meta-analysis,
Grosso and colleagues (2014) created categories of the purity of supplements (e.g., mainly EPA,
pure EPA). In addition, the researchers noted a widespread length of time in the trials from 4
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weeks to 160 weeks. In addition, each type of ω-3 (DHA, EPA, ALA) has shown to demonstrate
differing effects on biological processes (Dyall, 2015), supporting the notion that standardization
of ω-3 supplements administered in research trials is essential. The inconsistency across methods
is a critical weakness within the literature, thus, it is challenging to evaluate the literature and to
infer any robust conclusions between ω-3 FA and mental health outcomes. Thus, it is necessary
for researchers to develop standard recommendations across ω-3 types, dosages, and durations
within clinical trials in order to productively move forward in this field of research.
There is continually a demand to improve assessment methods when conducting research,
particularly within nutrition research. Many researchers utilize food frequency questionnaires,
food diaries, and 24-hour recall methods to assess diet. Dietary self-report measures have
consistently shown to result in underreporting of energy intake (Freedman et al., 2014) and are
inaccurate due to poor evaluation of portion size or have an incomplete list of foods (Thompson
& Subar, 2017). Incorporating the use of objective assessment measures such as blood samples
(Johnston, Deuster, Harris, Macrae, & Dretsch, 2013) can improve accuracy in nutritional
assessments and avoid participant biases in diet recall methods. Additionally, it would be
beneficial for researchers to objectively assess both ω-6 and ω-3 FA levels. As mentioned earlier,
there is controversy regarding the significance of the ω-6 to ω-3 ratio, however many studies
only assess ω-3 FA levels. Including the assessment of various ω-6 FAs would increase our
understanding of the role of ω-6 FAs on physical and mental health outcomes.
Examining ethnicity more rigorously within ω-3 research is necessary given the clear
baseline differences in ω-3 levels across races. Our study found higher levels of ω-3 levels in
participants that identified as Asian/Pacific Islander and Black, compared to White and Hispanic
participants. These variations have been identified in the literature (Villegas, Takata, Murff, &
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Blot, 2016; Xiao et al., 2016). It is also been noted that individuals of Japanese descent have
much higher concentrations of ω-3 levels compared to Americans (Iso et al., 1989). It is
important for researchers to gather an accurate assessment of racial/cultural background, dietary
history, and regional location of their participants prior to enrollment in a clinical trial in order to
stratify their sample appropriately. This will increase the likelihood of well-defined results and a
clearer understanding of the implications of ω-3 supplementation. Furthermore, given the
differences in ω-3 levels across racial backgrounds, there are likely varying needs for different
races. For instance, one review of nearly 300 studies evaluated EPA and DHA levels across
countries globally (Stark, Van Elswyk, Higgins, Weatherford, & Salem, 2016). The authors
identified a large amount of variability in ω-3 levels across regions, with those in the very low
range potentially having an increased risk of chronic illness. Thus, ω-3 recommendations may
not be consistent across racial groups and those with lower levels ω-3 will likely require higher
ω-3 dosages.
Based on our current findings, a next phase of research would be to develop an RCT
investigating the impact of different types of ω-3 supplementation, such as, EPA versus DHA
predominant formulas, across individuals with varying degrees of clinical symptoms, such as,
subthreshold versus clinical levels of depression and anxiety. Utilizing diagnostic clinical
interviews to evaluate the severity of psychological symptoms would be ideal. It would be
important to stratify the sample by racial background due to variances across ω-3 FA levels.
Another option would be to create a less ethnically diverse sample to help remove any
confounding racial effects. Moreover, with the RCT, it will be necessary to utilize objective
measures of ω-3 assessment (e.g., blood samples) to eliminate the potential of underreporting via
self-report measures. Measuring ω-3 levels at multiple time-points (e.g., baseline, mid-
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assessment, post-assessment, follow-up) would also shed light on the ways in which ω-3 FAs
metabolize and how long ω-3 FAs remain within the human body.
Additional work needs to be done within psychological nutrition research to improve the
standardization across trials. Specific recommendations have been suggested including
developing consistency across the dosage and duration of ω-3 supplements administered,
improving the measurement of diet and psychological symptoms, increasing diversity within
samples, and designing clinical trials that test mediation (Polokowski, Shakil, Carmichael, &
Reigada, 2018). These are some strategies to gain better insight into the ways in which ω-3 FAs
may be related to psychological symptoms.
Clinical Implications
As rates of mental health disorders increase, it is necessary to evaluate lifestyle factors
that may impact these disorders, as these factors have been overlooked in psychological
intervention research. Nutrition has been identified as one avenue of research that relates to
multiple biological mechanisms which may in turn influence anxiety and depression.
Implementing dietary assessment and interventions into evidence-based practices can be costeffective and more easily tolerated than psychotropic medications (Freeman et al., 2006;
Mozaffarian & Rimm, 2006). With increased attention focused on the connection between
nutrition and mental health, there is promising research supporting the importance of diet as a
favorable therapeutic option for managing psychological well-being.
Assessing Diet in Clinical Practice
Although nutritional status has been identified as an important component to mental
health, clinicians are not provided standardized training to assess diet in their patients and
therefore do not routinely inquire about their patient’s dietary intake (Burks & Keeley, 1989;
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Terry & Reeves, 2015). The biopsychosocial framework is a valuable model when intervening
with diet because it considers the biological, social, psychological, and environmental factors
associated with health behaviors (Suls & Rothman, 2004). Furthermore, with the expansion of
multidisciplinary teams, clinicians will have increased access to dieticians or nutritionists to
consult with or make referrals when they need additional support surrounding patients’ dietary
issues.
There are multiple ways to evaluate diet in the context of mental health care including
assessing food selection, supplementation, or deficiencies (Walsh, 2011). Conducting a basic
assessment of a patient’s diet may help guide treatment recommendations. For instance, caffeine
has shown to increase anxiety and psychotic symptoms and impact sleep, thus a simple
assessment of caffeine intake is recommended as part of any psychiatric assessment (Winston,
Hardwick, Jaberi, 2005). It is also suggested that clinicians inquire about nutritional
supplements, as many patients assume they are harmless, yet they have the potential to
negatively interact with pharmaceutical drugs (Singh, 2005). With a brief assessment of diet,
mental health professionals have the opportunity to discover key features of their patients which
may influence treatment recommendations.
Incorporating Dietary Interventions into Clinical Practice
Dietary and nutritional supplements have been explored in relation to psychological
health. For instance, a review article reported that low levels of folate (a B-vitamin) and vitamin
B-12, have been found in samples of depressed patients (Coppen & Bolander-Gouaille, 2005).
Furthermore, depressed patients responded better to antidepressant medication when folate and
vitamin B-12 levels were higher (Coppen & Bolander-Gouaille, 2005; Miller, 2008). A recent
meta-analysis examining the efficacy of adding nutritional supplements to antidepressant
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concluded that overall results are inconclusive due to mixed results across studies, however there
is some support for the supplementation of zinc and ω-3 FAs (Schefft, Kilarski, Bschor, Kohler,
2017). Thus, some of the literature supports the notion that adding supplements to established
therapeutic practices may increase efficacy, with ω-3 FAs in particular showing benefit (Dome,
Tombor, Lazary, Gonda, & Rihmer, 2019).
There is evidence that consuming ω-3 FAs via diet (e.g., salmon, enriched yogurt)
demonstrate increased levels of plasma EPA and DHA (Elvevoll et al., 2006; Rise, Colombo,
Ghezzi, Mauro, & Orlandini, 2011) compared to taking an ω-3 FA supplement (Ratnayake &
Galli, 2009). Additionally, there is some evidence that consuming an ω-3 FA supplement with a
meal high in fat may improve absorption of fatty acids (Opperman, 2013). Accordingly, if it is
feasible for patients, it is recommended to consume ω-3 FAs via dietary intake as it seems this
method has more advantageous effects compared to supplementation alone. Based on our
findings, DHA in particular seemed to be related to psychological outcomes. Thus, it is
recommended that foods higher in DHA such as seafood be incorporated into a patient’s
treatment plan may be a simple yet effective intervention. Additionally, based on the present
study, it seems that practical applications should aim to target more severe clinical samples, as
they demonstrate more benefit from ω-3 FA supplementation.
Common Barriers in Dietary Interventions.
It is known that individuals with higher rates of anxiety and depressive symptoms
generally have poorer lifestyle behaviors (e.g., poorer diets) which may have influenced our
findings (Parletta, Aljeesh, and Baune, 2016), for instance, they would be less likely to consume
ω-3 FAs or diets that may increase healthy gut bacteria. In practice, there are multiple factors to
consider when investigating and intervening with dietary habits including access to food, social
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economic status, nutritional education, living environments and cultural values. It has been found
that individuals with a lower socioeconomic status are exposed to poorer quality food options
which results in unhealth eating patterns (Ford & Dzewaltowski, 2008). Additionally, individuals
are consuming more calories than ever before due to our culture being flooded by fast food
restaurants, larger portion sizes, and an increase in energy dense foods, all for a low cost
(Drewnowski & Darmon, 2005). Results from a meta-analysis show that on average, eating a
healthier diet, such as fruits, vegetables, fish, and nuts, is more expensive than consuming a less
healthy diet consisting of meats and refined grains (Rao, Afshin, Singh, & Mozaffarian, 2013).
Many patients may not have the means or accessibility to access certain food options. Thus,
clinicians may face larger challenges when attempting to provide dietary recommendations and
must consider social and environmental factors.
Although significant work is still needed, developing clinical interventions that
incorporate a dietary component may be a noteworthy next step in treating psychological
conditions.
Conclusion
As there are drastic shifts in diets across the globe, the literature continues to identify
trends in how diet is associated with mental health outcomes. Specifically, ω-3 FAs possess
numerous physical and mental health benefits and are acknowledged as a necessary component
of a healthy lifestyle. Recently, there has been an increase in research investigating potential
biological mechanisms that may clarify the ways in which ω-3 FAs may prevent or treat mental
health symptoms. Furthermore, growing evidence suggests that the gut microbiome promotes or
prevents inflammatory responses which in turn may lead to neuropsychiatric disorders. The
present study aimed to expand empirical efforts to explore the utility of ω-3 fatty acids by
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gaining a greater understanding of the impact on inflammation, gut bacteria, and mental health
outcomes.
Main findings from the current study demonstrated that higher levels of ω-3 index and
DHA significantly predicted fewer trait-anxiety and fewer depressive symptoms suggesting that
ω-3 supplementation may demonstrate benefit over mental health symptoms. Moreover, higher
levels of inflammatory markers IL-1β and IL-6 were shown to significantly predict higher levels
of stress symptoms, while higher levels of EPA significantly predicted higher levels of IL-6.
Lastly, greater abundance of gut bacteria Lactobacillus significantly predicted higher levels of
IL-8. We are in the preliminary stages of understanding the ways in which specific nutritional
components such as ω-3 FAs, may have an impact on psychological health, yet researchers must
improve the methodology examining these variables in order to develop meaningful conclusions.
In order to utilize ω-3 FAs as therapeutic option for depression and anxiety, we must first
understand the mechanisms by which they operate to develop the most effective treatment
options.
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ALA: α -linolenic acid
AA: Arachidonic acid
BDI: Beck Depression Inventory
CRP: C-reactive protein
DHQ: Diet History Questionnaire
DHA: Docosahexaenoic acid
EFA: Essential Fatty Acid
EPA: Eicosapentaenoic acid
GIT: Gastrointestinal tract
GAD: Generalized Anxiety Disorder
ILD-6: Interleukin 6
IL-8: Interleukin 8
IL-1b. Interleukin 1 beta
LA: Linoleic acid
MDD: Major Depressive Disorder
MeSH: Medical subject headings
OCD: Obsessive-Compulsive Disorder
ω-3 FAs: Omega-3 fatty acids
ω-6 FAs: Omega-6 fatty acids
PSS: Perceived Stress Scale
TNF-α: Tumor necrosis factor alpha
STAI: State-Trait Anxiety Inventory
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Appendices
Appendix A. Informed Consent

THE CITY UNIVERSITY OF NEW YORK
Brooklyn College
Department of Psychology

CONSENT TO PARTICIPATE IN A RESEARCH STUDY

Title of Research Study:

The Relationship between Diet, Inflammation, Gut Flora and
Mental Health

Principal Investigator:

Ashley Polokowski, M.A.
Graduate Student
Brooklyn College
2900 Bedford Ave., James Hall Room 5309A
Brooklyn, NY, 11210
718-951-5000 ext. 6651

Faculty Advisor:

Laura Reigada, Ph.D.
Assistant Professor
Brooklyn College
2900 Bedford Ave., James Hall Room 5309B
Brooklyn, NY, 11210
718-951-5000 ext. 6021
Schwab Donor Advised Fund

Research Sponsor:

You are being invited to participate in a research study because you are at least 18 years of
age, are not pregnant, have not been diagnosed with inflammatory or endocrine disorders,
have not been diagnosed with any psychiatric disorders, do not drink or smoke excessively,
do not use psychoactive drugs, do not have a history of drug abuse, have not been in
treatment (psychotherapy and/or medication) for anxiety less than 6 months, and you have
notified the researchers of any food allergies you have, particularly to fish.
Purpose:
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The purpose of this research study is to understand the relationship between the bacteria
present in our gut, inflammation, the food we eat, and our mood. The results of this study
will show how these elements are connected and how imbalances in some elements could
influence the others.
Procedures:
If you volunteer to participate in this research study, we will ask you to do the following:
Time

Pre-test
(Day 0)

Pre-test
(Day 0)
Experime
nt
(Week 1Week 12)

Location

Activity
Meet with Principal Investigator (PI) or Research Personnel

Complete multiple questionnaires:
1. Demographic Questionnaire (e.g., age, sex, ethnicity)
2. Diet History Questionnaire (DHQ): assesses regular eating habits
3. State-Trait Anxiety Inventory (STAI): evaluates anxiety
Brooklyn College symptoms
Psychology Lab,
4. Beck Depression Inventory (BDI): evaluates depressive
James Hall,
symptoms
Room 4611 or
5. Perceived Stress Scale (PSS): evaluates stress symptoms
Room 5309,
2900 Bedford
• Provide a saliva sample
Ave, Brooklyn,
• Receive a stool sampling kit and directions on collecting stool
NY (“REACH
samples and submitting kit to PI or mailing to external laboratory
Lab”)
• Receive supply of omega-3 fatty acid pills, probiotic, or
combination of both, and directions on taking the supplements
• Receive directions on diet and lifestyle habits to avoid or to note
during experiment
• Receive directions on recording omega-3 and omega-6 content
throughout the week
In private collect own stool sample and follow directions to submit to
In private
external lab via mail, or return kit to research staff to submit via mail
In private

Take supplements daily as directed
Record diet once per week
Return to REACH Lab to meet with PI

Post-test
(Week 13)

REACH Lab

Complete multiple questionnaires:
1. Demographic Questionnaire
2. Diet History Questionnaire (DHQ)
3. State-Trait Anxiety Inventory (STAI)
4. Beck Depression Inventory (BDI)
5. Perceived Stress Scale (PSS)
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•
•
Post-test
(Week 13)
Debriefin
g

In private
REACH Lab

Provide a saliva sample
Receive a stool sampling kit and directions on collecting stool
samples and submitting kit to PI or mailing to external laboratory
In private collect own stool sample and follow directions to submit to
outside lab via mail, or return kit to research staff to submit via mail
Return to REACH lab after providing stool sample to debrief on the
experiment performed.

Time Commitment:
Your participation in this research study is expected to last for a total of 13 weeks.
Potential Risks or Discomforts:
• The study involves minimal risk for breach of confidentiality.
•

For Questionnaires: If the sensitive nature of some of the questions regarding mood
causes you distress and you would like to speak to a mental health professional, or
you would like to obtain mental health services for any reason, please contact the
Brooklyn College Personal Counseling Center in room 0203 in James Hall, 2900
Bedford Ave, Brooklyn, NY or call them at 718-951-5363. Additionally, a Suicide
Prevention hotline can also be contacted 24 hours a day at 1-800-273-8255.
Alternatively, call 911 or go to the nearest hospital emergency room if you believe
that you may be in danger of harming yourself or anyone else.

•

For stool sample: You may feel uncomfortable providing a stool sample. The
researchers have provided you an individual kit with directions which you can use to
collect your stool in private. You have the option of mailing out your sample via mail
to uBiome, the stool testing service, yourself or can give your individual kit to the
research staff to mail out. All personal information provided them will remain
confidential and you will be provided the privacy practices of uBiome upon request.

•

For taking Supplements:
o Consuming omega-3 fatty acid supplements, or fish oil pills, have generally
been found to be safe but people in previous studies have reported side effects
such as burping and a mild fishy aftertaste, or diarrhea. Taking capsules with
meals minimizes these side effects. Omega-3 fatty acids may become toxic if
oxidized, but this can be prevented by refrigerating the pills before
consumption. Although not found as dangerous, omega-3s may also impact
your cholesterol and triglyceride levels, which you may want to monitor with
your doctor.
o Probiotics are generally regarded as safe and can be found naturally in dairy
and fermented products such as yogurt. Although very rare, probiotics possess
the risk of causing bacteria in the blood and inflammation of the inner heart
lining especially in patients with impaired immune systems.
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Potential Benefits:
• This study will help you gain essential dietary nutrients recommended by the
American Heart Association and the Federal Government.
o Studies suggest that consumption of omega-3 fatty acids could improve
cholesterol profiles of people by increasing HDL and decreasing LDL and could
decrease your risk of breast cancer. Studies have also shown benefits of
omega-3 fatty acids for people with cardiovascular disease, Type II Diabetes
Mellitus, and Rheumatoid Arthritis.
o Studies also suggest that consumption of probiotics have beneficial effects and
could potentially lower cholesterol, hypertension, and postmenopausal
symptoms, prevent diarrhea, and might even help people with lactose
intolerance or other food allergies.
o Lastly, your participation will also benefit a new area of research by helping
us understand how what we eat can affect our mood.
Alternatives to Participation:
The alternative to study participation is not to participate. You may wish to consult your
primary care physician before participating. Aside from compensation for participating you
will not be reimbursed for visiting a doctor and it is your responsibility to speak with your
doctor if you decide to do so. You have the option not to participate in the study.
Costs
All program-related costs (e.g., supplement pills) associated with this study, with the
exception of travel expenses to the lab, will be provided to you.
Payment for Participation:
To compensate you for the time spent at the pre- and post-test, you will receive $25 at both
time points. No reimbursement will be provided if the final assessment is not completed.
Research Related Injury
In the event of injury resulting from your participation in this research study, the facilities
at Brooklyn College and professional attention will be made available to you at your
expense. Financial compensation from Brooklyn College will not be provided. If you believe
that you have suffered an injury related to this research as a participant in this study, you
should contact the research staff.
New Information:
You will be notified about any new information regarding this study that may affect your
willingness to participate in a timely manner.
Confidentiality:
We will make our best efforts to maintain confidentiality of any information that is collected
during this research study, and that can identify you. We will disclose this information only
with your permission or as required by law.
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We will protect your confidentiality by storing all identifying information (name and email)
in a password-protected file saved on a study flash drive stored in a locked office. Identifying
information will be kept separate from all other study data to ensure confidentiality.
Additionally, all questionnaires, saliva samples, computer tasks and worksheets will only
include your participant ID and de-identified paper forms will be stored in a cabinet in a
locked office. The list with identifying information will be destroyed upon completion of data
collection. Consent forms with names will be stored separately in a locked office, will not
include any linking information (i.e., ID number) and will be destroyed after 3 years.
You have the option to either directly mail their fecal samples to uBiome or to have the
research team mail them on your behalf. The research team will not store any fecal samples
and will dispose of any extras that you may provide. Any personal health information that
you provide will be protected by the uBiome privacy practices; uBiome is required by the
Health Insurance Portability and Accountability Act of 1996 (HIPAA) to keep all health
information confidential.
If the investigators learn that you or someone with whom you are involved is in serious
danger of potential severe harm, they may need to warn those who are in danger and contact
other agencies to ensure safety.
The research team, authorized CUNY staff, the research sponsor, and government agencies
that oversee this type of research may have access to research data and records in order to
monitor the research. Research records provided to authorized, non-CUNY individuals will
not contain identifiable information about you. Publications and/or presentations that result
from this study will not identify you by name.
Participants’ Rights:
•

Your participation in this research study is entirely voluntary. If you decide not to
participate, there will be no penalty to you, and you will not lose any benefits to which
you are otherwise entitled.

•

Your participation or non-participation in this study will in no way affect your grades,
your academic standing with CUNY, or any other status in the College.

•

Your participation or non-participation in this study will in no way affect your
employment at Brooklyn College.

•

You can decide to withdraw your consent and stop participating in the research at
any time, without any penalty.

Questions, Comments or Concerns:
If you have any questions, comments or concerns about the research, you can contact the
Principal Investigator, Ashley Polokowski at 718-951-5000 ext. 6651, or at
apolokowski@brooklyn.cuny.edu. If you have questions about your rights as a research
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participant, or you have comments or concerns that you would like to discuss with someone
other than the researchers, please call the CUNY Research Compliance Administrator at 646664-8918 or email HRPP@cuny.edu. Alternately, you can write to:
CUNY Office of the Vice Chancellor for Research
Attn: Research Compliance Administrator
205 East 42nd Street
New York, NY 10017
Signature of Participant:
If you agree to participate in this research study, please sign and date below. You will be
given a copy of this consent form to keep.
_____________________________________________________
Printed Name of Participant
_____________________________________________________
__________________________
Signature of Participant
Date
Signature of Individual Obtaining Consent
_____________________________________________________
Printed Name of Individual Obtaining Consent
_____________________________________________________
Signature of Individual Obtaining Consent

__________________________
Date
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Appendix B. Demographic Form
Date (m/d/y):_________

ID#:___________

Baseline Demographic Information
1. What is your age? _________
2. Please specify your gender. _____________
3. Please specify your ethnicity.
White
Hispanic or Latino
Black or African American
Native American or American Indian
Asian / Pacific Islander
Other ___________
4. What is the highest degree or level of school you have completed? If currently enrolled,
highest degree received.
No schooling completed
Nursery school to 8th grade
Some high school, no diploma
High school graduate, diploma or the equivalent (for example: GED)
Some college credit, no degree
Trade/technical/vocational training
Associate degree
Bachelor’s degree
Master’s degree
Professional degree
Doctorate degree
5. What is your marital status?
Single, never married
Married or domestic partnership
Widowed
Divorced
Separated
6. Are you currently…?
Employed for wages
Self-employed
Out of work and looking for work
Out of work but not currently looking for work
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A homemaker
A student
Military
Retired
Unable to work
6A. If you are working, how many hours a week do you work? ________
7. What was your total household income during the past 12 months?
Less than $25,000
$25,000 to $34,999
$35,000 to $49,999
$50,000 to $74,999
$75,000 to $99,999
$100,000 to $149,999
$150,000 or more
8. If you were born in the United States, which region of the country were you born in?
New England - Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island,
Vermont
Middle Atlantic - New Jersey, New York, Pennsylvania
East North Central - Illinois, Indiana, Michigan, Ohio, Wisconsin
West North Central - Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, South
Dakota
South Atlantic - Delaware, District of Columbia, Florida, Georgia, Maryland, North
Carolina, South Carolina, Virginia, West Virginia
East South Central - Alabama, Kentucky, Mississippi, Tennessee
West South Central - Arkansas, Louisiana, Oklahoma, Texas
Mountain - Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, Wyoming
Pacific - Alaska, California, Hawaii, Oregon, Washington
8A. How long did you live there? ____________________
9. If you were not born in the United States, what country were you born in?
____________________________________________________________________________
9A. How long did you live there? ____________________
10. What neighborhood do you currently live in? __________________________________
11. How many people currently live in your household? ____________________________
12. Please list any allergies that you have.
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
13. Please list any dietary restrictions you have.
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______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
14. Please note any past or current treatment for anxiety.
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
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Appendix C. Perceived Stress Scale

PERCEIVED STRESS SCALE

The questions in this scale ask you about your feelings and thoughts during the last month. In
each case, you will be asked to indicate by circling how often you felt or thought a certain way.
Name ____________________________________________________________
Date ______________
Age ________
Gender (Circle): M F Other _____________________________________

0 = Never 1 = Almost Never 2 = Sometimes 3 = Fairly Often 4 = Very Often
1. In the last month, how often have you been
0
1
2
3
upset because of something that happened
unexpectedly?
2. In the last month, how often have you felt
0
1
2
3
that you were unable to control the important
things in your life?
3. In the last month, how often have you felt
0
1
2
3
nervous and “stressed”?
4. In the last month, how often have you felt
0
1
2
3
confident about your ability to handle your
personal problems?
5. In the last month, how often have you felt
0
1
2
3
that things were going your way?
6. In the last month, how often have you found
0
1
2
3
that you could not cope with all the things that
you had to do?
7. In the last month, how often have you been
0
1
2
3
able to control irritations in your life?
8. In the last month, how often have you felt
0
1
2
3
that you were on top of things?
9. In the last month, how often have you been
0
1
2
3
angered because of things that were outside of
your control?
10. In the last month, how often have you felt
0
1
2
3
difficulties were piling up so high that you could
not overcome them?

4
4
4
4
4
4
4
4
4
4
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Appendix D. State-Trait Anxiety Inventory
SELF-EVALUATION QUESTIONNAIRE STAI Form Y-1
Please provide the following information:
Name _________________________________________ Date_____________ S ______
Age __________________ Gender (Circle) M F
T ______
DIRECTIONS:
A number of statements which people have used to describe themselves are given below. Read
each statement and then blacken the appropriate circle to the right of the statement to indicate
how you feel right now, that is, at this moment. There are no right or wrong answers. Do not
spend too much time on any one statement but give the answer which seems to describe your
present feelings best.
1 = Not At All 2 = Somewhat 3 = Moderately So 4 = Very Much So
1. I feel calm.......................................................................................................................... 1 2 3 4
2. I feel secure........................................................................................................................ 1 2 3 4
3. I am tense .......................................................................................................................... 1 2 3 4
4. I feel strained ..................................................................................................................... 1 2 3 4
5. I feel at ease ...................................................................................................................... 1 2 3 4
6. I feel upset.......................................................................................................................... 1 2 3 4
7. I am presently worrying over possible misfortunes........................................................... 1 2 3 4
8. I feel satisfied..................................................................................................................... 1 2 3 4
9. I feel frightened.................................................................................................................. 1 2 3 4
10. I feel comfortable............................................................................................................. 1 2 3 4
11. I feel self-confident.......................................................................................................... 1 2 3 4
12. I feel nervous ................................................................................................................... 1 2 3 4
13. I am jittery........................................................................................................................ 1 2 3 4
14. I feel indecisive................................................................................................................ 1 2 3 4
15. I am relaxed...................................................................................................................... 1 2 3 4
16. I feel content ................................................................................................................... 1 2 3 4
17. I am worried..................................................................................................................... 1 2 3 4
18. I feel confused.................................................................................................................. 1 2 3 4
19. I feel steady...................................................................................................................... 1 2 3 4
20. I feel pleasant................................................................................................................... 1 2 3 4
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SELF-EVALUATION QUESTIONNAIRE STAI Form Y-2
Name _________________________________________ Date_____________
DIRECTIONS:
A number of statements which people have used to describe themselves are given below. Read
each statement and then blacken in the appropriate circle to the right of the statement to indicate
you generally feel.
1 = Almost Never = Sometimes 3 = Often 4 = Almost Always
21. I feel pleasant................................................................................................................... 1 2 3 4
22. I feel nervous and restless................................................................................................ 1 2 3 4
23. I feel satisfied with myself............................................................................................... 1 2 3 4
24. I wish I could be as happy as others seem to be ............................................................. 1 2 3 4
25. I feel like a failure............................................................................................................ 1 2 3 4
26. I feel rested....................................................................................................................... 1 2 3 4
27. I am “calm, cool, and collected”...................................................................................... 1 2 3 4
28. I feel that difficulties are piling up so that I cannot overcome them............................... 1 2 3 4
29. I worry too much over something that really doesn’t matter........................................... 1 2 3 4
30. I am happy........................................................................................................................ 1 2 3 4
31. I have disturbing thoughts................................................................................................ 1 2 3 4
32. I lack self-confidence....................................................................................................... 1 2 3 4
33. I feel secure...................................................................................................................... 1 2 3 4
34. I make decisions easily ................................................................................................... 1 2 3 4
35. I feel inadequate............................................................................................................... 1 2 3 4
36. I am content...................................................................................................................... 1 2 3 4
37. Some unimportant thought runs through my mind and bothers me................................. 1 2 3 4
38. I take disappointments so keenly that I can’t put them out of my mind ......................... 1 2 3 4
39. I am a steady person......................................................................................................... 1 2 3 4
40. I get in a state of tension or turmoil as I think over my recent concerns and interests.... 1 2 3 4
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Appendix E. Beck Depression Inventory
Beck's Depression Inventory
This depression inventory can be self-scored. The scoring scale is at the end of the questionnaire.
1.
0 I do not feel sad.
1 I feel sad
2 I am sad all the time and I can't snap out of it.
3 I am so sad and unhappy that I can't stand it.
2.
0 I am not particularly discouraged about the future.
1 I feel discouraged about the future.
2 I feel I have nothing to look forward to.
3 I feel the future is hopeless and that things cannot improve.
3.
0 I do not feel like a failure.
1 I feel I have failed more than the average person.
2 As I look back on my life, all I can see is a lot of failures.
3 I feel I am a complete failure as a person.
4.

0 I get as much satisfaction out of things as I used to.
1 I don't enjoy things the way I used to.
2 I don't get real satisfaction out of anything anymore.
3 I am dissatisfied or bored with everything.

5.

0 I don't feel particularly guilty
1 I feel guilty a good part of the time.
2 2 I feel quite guilty most of the time.
3 I feel guilty all of the time.

6.

0 I don't feel I am being punished.
1 I feel I may be punished.
2 I expect to be punished.
3 I feel I am being punished.

7.

0 I don't feel disappointed in myself.
1 I am disappointed in myself.
2 I am disgusted with myself.
3 I hate myself.

8.

0 I don't feel I am any worse than anybody else.
1 I am critical of myself for my weaknesses or mistakes.
2 I blame myself all the time for my faults.
3 I blame myself for everything bad that happens.

9.

0 I don't have any thoughts of killing myself.
1 I have thoughts of killing myself, but I would not carry them out.
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2 I would like to kill myself.
3 I would kill myself if I had the chance.
10.

0 I don't cry any more than usual.
1 I cry more now than I used to.
2 I cry all the time now.
3 I used to be able to cry, but now I can't cry even though I want to.

11.

0 I am no more irritated by things than I ever was.
1 I am slightly more irritated now than usual.
2 I am quite annoyed or irritated a good deal of the time.
3 I feel irritated all the time.

12.

0 I have not lost interest in other people.
1 I am less interested in other people than I used to be.
2 I have lost most of my interest in other people.
3 I have lost all of my interest in other people.

13.

0 I make decisions about as well as I ever could.
1 I put off making decisions more than I used to.
2 I have greater difficulty in making decisions more than I used to.
3 I can't make decisions at all anymore.

14.

0 I don't feel that I look any worse than I used to.
1 I am worried that I am looking old or unattractive.
2 I feel there are permanent changes in my appearance that make me look unattractive
3 I believe that I look ugly.

15.

0 I can work about as well as before.
1 It takes an extra effort to get started at doing something.
2 I have to push myself very hard to do anything.
3 I can't do any work at all.

16.

0 I can sleep as well as usual.
1 I don't sleep as well as I used to.
2 I wake up 1-2 hours earlier than usual and find it hard to get back to sleep.
3 I wake up several hours earlier than I used to and cannot get back to sleep.

17.

0 I don't get more tired than usual.
1 I get tired more easily than I used to.
2 I get tired from doing almost anything.
3 I am too tired to do anything.

18.

0 My appetite is no worse than usual.
1 My appetite is not as good as it used to be.
2 My appetite is much worse now.
3 I have no appetite at all anymore.

19.

0 I haven't lost much weight, if any, lately.

106
1 I have lost more than five pounds.
2 I have lost more than ten pounds.
3 I have lost more than fifteen pounds.
20.

0 I am no more worried about my health than usual.
1 I am worried about physical problems like aches, pains, upset stomach, or constipation.
2 I am very worried about physical problems and it's hard to think of much else.
3 I am so worried about my physical problems that I cannot think of anything else.

21.

0 I have not noticed any recent change in my interest in sex.
1 I am less interested in sex than I used to be.
2 I have almost no interest in sex.
3 I have lost interest in sex completely.
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Appendix X. Skewness, Kurtosis, and Shapiro-Wilk Values for Study Variables
Skewness
Skewness Shapiro-Wilk
Kurtosis
Study Variable
(Std. Error)
Z-score
(p-value)
(Std. Error)

Kurtosis
Z-score

PSS
STAI-State
STAI-Trait
BDI

-0.148 (0.271)
0.565 (0.271)
0.065 (0.271)
0.692 (0.271)

0.546
2.085*
0.240
2.553*

0.982 (0.345)
0.961 (0.016)**
0.968 (0.045)**
0.953 (0.006)**

-0.555 (0.535)
-0.238 (0.535)
-1.050 (0.535)
0.138 (0.535)

-1.037
-0.445
-2.804*
0.258

DHA
EPA
ALA
Omega-3 Index

0.616 (0.271)
1.667 (0.271)
1.172 (0.271)
0.849 (0.271)

2.273*
6.151*
4.325*
3.133*

0.967 (0.041)**
0.887 (0.000)**
0.919 (0.000)**
0.952 (0.005)**

0.080 (0.535)
4.914 (0.535)
1.703 (0.535)
1.054 (0.535)

0.150
9.185*
3.183*
1.970

IL-1β
IL-6
IL-8
TNF-α

5.828 (0.271)
4.792 (0.271)
2.895 (0.271)
8.597 (0.271)

21.506*
17.683*
10.683*
31.723*

0.442 (0.000)**
0.383 (0.000)**
0.696 (0.000)**
0.151 (0.000)**

41.627 (0.535)
24.087 (0.535)
10.264 (0.535)
75.321 (0.535)

77.807*
45.022*
19.185*
140.787*

Lactobacillus
Bifidobacterium

4.865 (0.293)
2.242 (0.293)

16.604*
7.652*

0.357 (0.000)**
0.721 (0.000)**

25.707 (0.578)
5.510 (0.578)

44.476*
9.533*

* Z-score is <-2 or >2
**Shaprio-Wilk < 0.05
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Appendix Y. Comparison of square root and logarithmic transformation of skewed independent
variables
Square Root Transformation
Skewness
Variable
(Std. Error)
BDI
-0.085 (0.271)
STAI-State
0.277 (0.271)
STAI-Trait
-0.127 (0.271)

Skewness
Z-score
-0.314
1.022
0.469

Shapiro-Wilk
(p-value)
0.984 (0.408)
0.977 (0.169)
0.969 (0.054)**

Kurtosis
Kurtosis
(Std. Error) Z-score
-0.537 (0.535) -1.004
-0.557 (0.535) -1.041
-0.972 (0.535) -1.817

0.303 (0.271)
0.813 (0.271)
0.656 (0.271)
0.561 (0.271)

1.118
3.000*
2.421*
2.070*

0.985 (0.461)
0.962 (0.18)**
0.963 (0.023)**
0.972 (0.076)

-0.381 (0.535)
1.597 (0.535)
0.816 (0.535)
0.223 (0.535)

2.577 (0.271)

9.509*

0.792 (0.000)**

3.301 (0.271)

12.181*

0.648 (0.000)**

IL-8
TNF-α

1.450 (0.271)

5.351*

0.895 (0.000)**

6.524 (0.271)

24.074*

0.402 (0.000)**

Lactobacillus
Bifidobacterium

2.748 (0.293)
0.824 (0.293)

9.379*
2.812*

0.673 (0.000)**
0.931 (0.001)**

8.949 (0.578)
0.261 (0.578)

15.483*
0.452

Skewness
Z-score
-3.690*

Shapiro-Wilk
(p-value)
0.918 (0.000)**

Kurtosis
(Std. Error)
0.595 (0.535)
-0.688
(0.535)
-0.753
(0.535)

Kurtosis
Z-score
1.112

DHA
EPA
ALA
Omega-3 Index
IL-1β
IL-6

10.788
(0.535)
12.978
(0.535)
3.259 (0.535)
49.783
(0.535)

-0.712
2.985*
1.525
0.417
20.164*
24.258*
6.092*
93.052*

* Z-score is <-2 or >2
**Shaprio-Wilk < 0.05
Logarithmic Transformation
Skewness
Variable
(Std. Error)
BDI
-1.000 (0.271)
STAI-State

-0.007 (0.271)

-0.026

0.982 (0.345)

STAI-Trait

-0.337 (0.271)

-1.244

0.964 (0.025)**

0.001 (0.271)

0.004

0.990 (0.795)

0.050 (0.271)
0.069 (0.271)

0.185
0.255

0.990 (0.788)
0.983 (0.317)

0.306 (0.271)

1.129

0.984 (0.409)

DHA
EPA
ALA
Omega-3 Index

-0.548
(0.535)
0.540 (0.535)
0.773 (0.535)
-0.279
(0.535)

-1.286
-1.407
-1.024
1.009
1.445
-0.521
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IL-1β
IL-6
IL-8
TNF-α
Lactobacillus
Bifidobacterium

0.124 (0.271)
1.006 (0.271)
0.058 (0.271)
1.256 (0.271)

0.458
3.712*
0.214
4.635*

0.990 (0.814)
0.934 (0.001)**
0.986 (0.534)
0.925 (0.000)**

-0.250 (0.293)

-0.853

0.954 (0.014)**

-1.164 (0.293)

-3.973*

0.929 (0.001)**

* Z-score is <-2 or >2
**Shaprio-Wilk < 0.05

0.410 (0.535)
2.518 (0.535)
0.275 (0.535)
4.647 (0.535)
-0.876
(0.578)
2.172 (0.578)

0.766
4.707*
0.514
8.686*
-1.521
3.758*
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Tables
Table 1. Demographic Characteristics (N = 79)
Characteristics
Age, years
Gender
Female
Ethnicity
Black
White
Hispanic/Latino
Asian/Pacific Islander
Mixed
Other
Household Income
Less than $25,000
$25,000-$34,999
$35,000-$49,999
$50,000-$74,999
$75,000-$99,999
$100,000-$149,999
$150,000 or more

M ± SD or N (%)
21.7 ± 4.1
79 (100.0)
20 (25.3)
19 (24.1)
19 (24.1)
12 (15.2)
6 (7.6)
3 (3.8)
27 (34.2)
9 (11.4)
13 (16.5)
16 (20.3)
4 (5.1)
3 (3.8)
7 (8.9)
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Table 2. Descriptive Statistics of Self-Report Measures (N = 79)
Measure
M ± SD
Range (Median)
PSS
20.0 ± 6.6
6.0 - 34.0 (20.0)
STAI-State
37.4 ± 10.8
20.0 – 67.0 (37.0)
STAI-Trait
44.9 ± 11.3
23.0 – 68.0 (45.0)
BDI
12.5 ± 8.0
1.0 – 35.0 (11.0)
Note. BDI = Beck Depression Inventory, PSS = Perceived Stress Scale,
STAI-State = State-Trait Anxiety Inventory-State, STAI-Trait = StateTrait Anxiety Inventory-Trait.
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Table 3. Mean and Standard Deviations for Biological
Measures
Measure
M ± SD
Omega-3 Level
DHA
2.69 ± 0.75
EPA
0.49 ± 0.21
ALA
0.50 ± 0.17
ω-3 Index
4.93 ± 1.03
Inflammatory Markers
IL-1β
IL-6
IL-8
TNF-α

135.0 ± 238.6
4.7 ± 9.0
725.9 ± 681.0
7.8 ± 37.9

Gut Bacteria
Lactobacillus
0.81 ± 0.30
Bifidobacterium
2.56 ± 0.43
Note. For gut bacteria results = (n = 67). ALA = Alphalinolenic Acid, DHA = Docosahexaenoic Acid, EPA =
Eicosapentaenoic Acid, IL-1β = Interleukin-1 Beta, IL-6 =
Interleukin-6, IL-8 = Interleukin-8, TNF-α = Tumor Necrosis
Factor Alpha, ω-3- Index = Omega-3 Index.
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Table 4. Spearman Correlations of ω-3 Levels and Self-report Measures (N = 79)
ω-3 Index
DHA
EPA
ALA
r (p-value)
r (p-value)
r (p-value)
r (p-value)
PSS
-0.19 (0.09)
-0.21 (0.06)
-0.07 (0.52)
-0.01 (0.92)
STAI-State
-0.08 (0.47)
-0.09 (0.46)
-0.03 (0.79)
-0.09 (0.42)
STAI-Trait
-0.29 (0.01)*
-0.30 (0.01)*
-0.18 (0.12)
0.04 (0.71)
BDI
-0.20 (0.07)
-0.21 (0.06)
-0.13 (0.24)
-0.08 (0.47)
*p<0.05

Note. ALA = Alpha-linolenic Acid, BDI = Beck Depression Inventory, DHA = Docosahexaenoic
Acid, EPA = Eicosapentaenoic Acid, PSS = Perceived Stress Scale, STAI-State = State-Trait
Anxiety Inventory-State, STAI-Trait = State-Trait Anxiety Inventory-Trait, ω-3- Index =
Omega-3 Index.
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Table 5. Spearman Correlations of ω-3 Levels and Inflammatory Markers (N = 79)
ω-3 Index
DHA
EPA
ALA
r (p-value)
r (p-value)
r (p-value)
r (p-value)
IL-1β
-0.26 (0.02)*
-0.24 (0.03)*
-0.20 (0.08)
-0.05 (0.65)
IL-6
-0.10 (0.39)
-0.14 (0.22)
-0.01 (0.95)
0.06 (0.59)
IL-8
-0.14 (0.23)
-0.14 (0.21)
-0.11 (0.34)
-0.02 (0.84)
TNF-α
-0.16 (0.17)
-0.15 (0.18)
-0.11 (0.35)
-0.02 (0.90)
*p<0.05

Note. ALA = Alpha-linolenic Acid, DHA = Docosahexaenoic Acid, EPA = Eicosapentaenoic
Acid, IL-1β = Interleukin-1 Beta, IL-6 = Interleukin-6, IL-8 = Interleukin-8, TNF-α = Tumor
Necrosis Factor Alpha, ω-3- Index = Omega-3 Index.
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Table 6. Spearman Correlations of ω-3 Levels and Gut Bacteria Abundance (N = 67)
ω-3 Index
DHA
EPA
ALA
r (p-value)
r (p-value)
r (p-value)
r (p-value)
Lactobacillus
-0.13 (0.29)
-0.09 (0.45)
-0.10 (0.40)
0.06 (0.65)
Bifidobacterium
-0.02 (0.89)
-0.01 (0.96)
-0.02 (0.88)
-0.09 (0.47)
Note. ALA = Alpha-linolenic Acid, DHA = Docosahexaenoic Acid, EPA = Eicosapentaenoic
Acid, ω-3- Index = Omega-3 Index.
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Table 7. Spearman Correlations of Gut Bacteria and
Self-report Measures (N = 67)
Lactobacillus
Bifidobacterium
r (p-value)
r (p-value)
PSS
-0.02 (0.89)
0.11 (0.37)
STAI-State
-0.05 (0.71)
0.16 (0.20)
STAI-Trait
-0.01 (0.96)
0.17 (0.16)
BDI
0.03 (0.84)
0.16 (0.21)
Note. BDI = Beck Depression Inventory, PSS = Perceived
Stress Scale, STAI-State = State-Trait Anxiety InventoryState, STAI-Trait = State-Trait Anxiety Inventory-Trait.
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Table 8. Spearman Correlations of Inflammatory Markers and Self-report Measures (N = 79)
IL-1β
IL-6
IL-8
TNF-α
r (p-value)
r (p-value)
r (p-value)
r (p-value)
PSS
0.21 (0.07)
0.15 (0.19)
0.07 (0.57)
0.05 (0.67)
STAI-State
0.14 (0.23)
-0.05 (0.67)
-0.05 (0.67)
-0.02 (0.89)
STAI-Trait
0.17 (0.13)
0.07 (0.55)
0.06 (0.62)
0.03 (0.80)
BDI
0.26 (0.02)*
0.17 (0.14)
0.14 (0.23)
0.11 (0.34)
*p<0.05

Note. BDI = Beck Depression Inventory, IL-1β = Interleukin-1 Beta, IL-6 = Interleukin-6, IL-8 =
Interleukin-8, PSS = Perceived Stress Scale, STAI-State = State-Trait Anxiety Inventory-State,
STAI-Trait = State-Trait Anxiety Inventory-Trait, TNF-α = Tumor Necrosis Factor Alpha.
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Table 9. Spearman Correlations of Gut Bacteria and
Inflammation (N = 67)
Lactobacillus
Bifidobacterium
r (p-value)
r (p-value)
IL-1β
0.11 (0.36)
-0.01 (0.96)
IL-6
-0.05 (0.67)
-0.05 (0.69)
IL-8
0.13 (0.31)
0.09 (0.45)
TNF-α
0.09 (0.50)
-0.04 (0.75)
Note.IL-1β = Interleukin-1 Beta, IL-6 = Interleukin-6, IL8 = Interleukin-8, TNF-α = Tumor Necrosis Factor Alpha.
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Table 10. Unstandardized Path Coefficients (standard error) for Serial Mediation Model of
Omega-3 Index on PSS
Lactoà Lactoà Lactoà Lactoà Bifidoà Bifidoà Bifidoà Bifidoà
IL-1β
IL-8
IL-6
TNF
IL-1β
IL-8
IL-6
TNF
a1
0.01
0.01
0.01
0.01
-0.11
-0.11
-0.11
-0.11
(0.30)
(0.30)
(0.30)
(0.30)
(0.43)
(0.43)
(0.43)
(0.43)
a2
-33.75
-74.52
0.11
1.39
-34.39
-71.53
0.13
1.31
(29.59)
(55.83)
(0.85)
(5.03)
(29.55)
(57.77)
(0.86)
(5.03)
d
8.07
57.96
0.42
-0.13
-6.96
21.45
0.18
-0.72
(12.30) (23.22)*
(0.35)
(2.09)
(8.50)
(16.63)
(0.25)
(1.45)
b1
0.18
0.14
0.15
0.23
0.18
0.09
0.09
0.11
(0.31)
(0.34)
(0.32)
(0.32)
(0.22)
(0.23)
(0.22)
(0.22)
b2
0.01
0.001
0.20
-0.02
0.01
0.002
0.20
-0.02
(0.003)* (0.002)
(0.11)†
(0.02)
(0.003)* (0.002)
(0.11)†
(0.02)
c’
-1.10
-1.23
-1.37
-1.32
-1.06
-1.21
-1.36
-1.31
(0.76)
(0.79)
(0.76)†
(0.78)†
(0.75)
(0.79)
(0.76)†
(0.79)†
c
-1.34
-1.34
-1.34
-1.34
-1.34
-1.34
-1.34
-1.34
(0.77)†
(0.77)†
(0.77)†
(0.77)†
(0.77)†
(0.77)†
(0.77)†
(0.77)†
IE
0.01
0.001
0.001
0.00
0.01
-0.004
-0.003
-0.001
(0.04)
(0.06)
(0.07)
(0.04)
(0.04)
(0.04)
(0.04)
(0.02)
95% -0.0753, -0.1561, -0.1950, -0.1153, -0.0672, -0.0951, -0.1103, -0.0491,
CIs
0.0887
0.1042
0.0713
0.0837
0.1044
0.0774
0.0800
0.0410
†p<0.10, *p<0.05, **p<0.01

Note. Bifido = Bifidobacterium, IE = Indirect Effect of the serial mediation, IL-1β = Interleukin1 Beta, IL-6 = Interleukin-6, IL-8 = Interleukin-8, Lacto = Lactobacillus, PSS = Perceived Stress
Scale, TNF-α = Tumor Necrosis Factor Alpha. 95 % CIs = the upper and lower 95 % confidence
intervals.
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Table 11. Unstandardized Path Coefficients (standard error) for Serial Mediation Model of
DHA on PSS
Lactoà Lactoà Lactoà Lacto
Bifidoà Bifidoà
Bifido Bifidoà
àTNF
àIL-6
IL-1β
IL-8
IL-6
IL-1β
IL-8
TNF
a1
0.12
0.12
0.12
0.12
-0.11
-0.11
-0.11
-0.11
(0.41)
(0.41)
(0.41)
(0.41)
(0.59)
(0.59)
(0.59)
(0.59)
a2
-50.87
-116.13
-0.50
-0.02
-50.56
-106.42
-0.43
0.12
(40.27)
(75.84)
(1.16)
(6.87)
(40.20)
(78.55)
(1.17)
(6.85)
d
8.59
59.15
0.43
-0.13
-6.91
21.57
0.17
-0.73
(12.28) (23.14)** (0.35)
(2.10)
(8.49)
(16.59)
(0.25)
(1.45)
b1
0.19
0.17
0.18
0.25
0.18
0.09
0.09
0.12
(0.31)
(0.34)
(0.32)
(0.32)
(0.22)
(0.23)
(0.22)
(0.22)
b2
0.01
0.001
0.19
-0.02
0.01
0.002
0.19
-0.02
(0.003)* (0.002)
(0.11)†
(0.02)
(0.003)*
(0.002)
(0.11)†
(0.02)
c’
-1.58
-1.78
-1.86
-1.95
-1.52
-1.73
-1.82
-1.91
(1.03)
(1.07)
(1.04)† (1.05)†
(1.03)
(1.07)
(1.04)†
(1.06)†
c
-1.92
-1.92
-1.92
-1.92
-1.92
-1.92
-1.92
-1.92
(1.05)†
(1.05)†
(1.05)† (1.05)†
(1.05)†
(1.05)†
(1.05)†
(1.05)†
IE
0.01
0.01
0.01
0.001
0.006
-0.004
-0.004
-0.001
(0.06)
(0.08)
(0.08)
(0.06)
(0.05)
(0.05)
(0.06)
(0.03)
95% -0.0891, -0.1958, -0.2193, -0.1494, -0.0907,
-0.1308, -0.1382, -0.0677,
CIs
0.1559
0.1714
0.1116
0.1424
0.1351
0.0912
0.0951
0.0479
†p<0.10, *p<0.05, **p<0.01

Note. Bifido = Bifidobacterium, DHA = Docosahexaenoic Acid, IE = Indirect Effect of the serial
mediation, IL-1β = Interleukin-1 Beta, IL-6 = Interleukin-6, IL-8 = Interleukin-8, Lacto =
Lactobacillus, PSS = Perceived Stress Scale, TNF-α = Tumor Necrosis Factor Alpha. 95 % CIs =
the upper and lower 95 % confidence intervals.
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Table 12. Unstandardized Path Coefficients (standard error) for Serial Mediation Model of
EPA on PSS
à
à
à
Lacto I Lacto
Lacto
Lactoà Bifido
Bifido
Bifido
Bifido
àIL-1β àIL-8
àIL-6
àTNF
L-1β
IL-8
IL-6
TNF
a1
-1.30
-1.30
-1.30
-1.30
-0.81
-0.81
-0.81
-0.81
(1.40)
(1.40)
(1.40)
(1.40)
(2.03)
(2.03)
(2.03)
(2.03)
a2
-51.94
-62.62
8.27
28.13
-67.15
-119.19
7.77
27.41
(141.55) (268.27) (3.89)* (23.61) (140.49) (275.15) (3.92)* (23.45)
d
7.48
57.17
0.51
-0.16
-6.86
21.72
0.20
-0.65
(12.50)
(23.68)*
(0.34)
(2.08)
(8.59)
(16.81)
(0.24)
(1.43)
b1
0.14
0.09
0.08
0.21
0.18
0.08
0.08
0.12
(0.32)
(0.34)
(0.33)
(0.33)
(0.22)
(0.23)
(0.22)
(0.22)
b2
0.01
0.002
0.24
-0.02
0.01
0.002
0.24
-0.02
(0.003)*
(0.002)
(0.12)*
(0.02) (0.003)* (0.002) (0.12)*
(0.02)
*
c’
-2.70
-2.99
-5.07
-2.66
-2.72
-3.03
-5.12
-2.85
(3.60)
(3.73)
(3.78)
(3.79)
(3.57)
(3.71)
(3.74)
(3.77)
c
-3.37
-3.37
-3.37
-3.37
-3.37
-3.37
-3.37
-3.37
(3.69)
(3.69)
(3.69)
(3.69)
(3.69)
(3.69)
(3.69)
(3.69)
IE
-0.08
-0.15
-0.16
0.003
0.05
-0.04
-0.04
-0.008
(0.20)
(0.28)
(0.30)
(0.25)
(0.19)
(0.20)
(0.24)
(0.11)
95%
-0.6996, -0.9008, -0.9403, -0.8505, -0.3324, -0.4168, -0.5330, -0.1969,
CIs
0.0712
0.1957
0.1676
0.0697
0.4655
0.3668
0.4760
0.2412
†p<0.10, *p<0.05, **p<0.01

Note. Bifido = Bifidobacterium, EPA = Eicosapentaenoic Acid, IE = Indirect Effect of the serial
mediation, IL-1β = Interleukin-1 Beta, IL-6 = Interleukin-6, IL-8 = Interleukin-8, Lacto =
Lactobacillus, PSS = Perceived Stress Scale, TNF-α = Tumor Necrosis Factor Alpha. 95 % CIs =
the upper and lower 95 % confidence intervals.
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Table 13. Unstandardized Path Coefficients (standard error) for Serial Mediation Model of ALA
on PSS
à
à
à
Lacto I Lacto
Lacto
Lactoà Bifidoà Bifidoà
Bifido Bifidoà
àIL-6
L-1β
IL-8
IL-6
TNF
IL-1β
IL-8
TNF
a1
-1.39
-1.39
-1.39
-1.39
0.66
0.66
0.66
0.66
(1.79)
(1.79)
(1.79)
(1.79)
(2.59)
(2.59)
(2.59)
(2.59)
a2
-131.10
-154.61
0.51
-15.33
-136.73
-248.17
-0.20
-14.55
(179.99) (341.77)
(5.14)
(30.39) (178.92)
(350.54)
(5.15)
(30.21)
d
7.14
56.78
0.43
-0.23
-6.45
22.46
0.18
-0.71
(12.43)
(23.61)*
(0.35)
(2.10)
(8.56)
(16.76)
(0.25)
(1.44)
b1
0.19
0.13
0.17
0.25
0.19
0.08
0.10
0.12
(0.32)
(0.34)
(0.33)
(0.33)
(0.22)
(0.23)
(0.23)
(0.23)
b2
0.01
0.002
0.20
-0.02
0.01
0.002
0.20
-0.02
(0.003)** (0.002)
(0.11)†
(0.02)
(0.003)**
(0.002)
(0.11)†
(0.02)
c’
3.66
2.90
2.48
2.31
3.32
2.67
2.18
1.89
(4.60)
(4.77)
(4.71)
(4.80)
(4.57)
(4.76)
(4.69)
(4.79)
c
2.23
2.23
2.23
2.23
2.23
2.23
2.23
2.23
(4.74)
(4.74)
(4.74)
(4.74)
(4.74)
(4.74)
(4.74)
(4.74)
IE
-0.08
-0.17
-0.12
-0.006
-0.04
0.03
0.02
0.008
(0.25)
(0.28)
(0.32)
(0.22)
(0.16)
(0.19)
(0.19)
(0.09)
95% -0.8056,
-0.6789, -0.4381, -0.6908, -0.4525,
-0.3045, -0.3223, -0.1904,
CIs
0.1522
0.4398
0.5743
0.1754
0.2580
0.4787
0.4739
0.2027
†p<0.10, *p<0.05, **p<0.01

Note. ALA = Alpha-linolenic Acid, Bifido = Bifidobacterium, IE = Indirect Effect of the serial
mediation, IL-1β = Interleukin-1 Beta, IL-6 = Interleukin-6, IL-8 = Interleukin-8, Lacto =
Lactobacillus, PSS = Perceived Stress Scale, TNF-α = Tumor Necrosis Factor Alpha. 95 % CIs =
the upper and lower 95 % confidence intervals.
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Table 14. Unstandardized Path Coefficients (standard error) for Serial Mediation Model of
Omega-3 Index on STAI-Trait
à
à
Lacto
Lacto
Lactoà Lactoà Bifidoà Bifidoà
Bifido Bifidoà
àIL-6
IL-1β
IL-8
IL-6
TNF
IL-1β
IL-8
TNF
a1
0.01
0.01
0.01
0.01
-0.11
-0.11
-0.11
-0.11
(0.30)
(0.30)
(0.30)
(0.30)
(0.43)
(0.43)
(0.43)
(0.43)
a2
-33.75
-74.52
0.11
1.39
-34.39
-71.53
0.13
1.31
(29.59)
(55.83)
(0.85)
(5.03)
(29.55)
(57.77)
(0.86)
(5.03)
d
8.07
57.96
0.42
-0.13
-6.96
21.45
0.18
-0.72
(12.30)
(23.22)*
(0.35)
(2.09)
(8.50)
(16.63)
(0.25)
(1.45)
b1
0.18
0.21
0.25
0.21
0.37
0.34
0.35
0.32
(0.56)
(0.59)
(0.56)
(0.56)
(0.39)
(0.39)
(0.39)
(0.38)
b2
0.004
-0.001
-0.09
-0.03
0.01
0.002
-0.09
-0.03
(0.01)
(0.003)
(0.20)
(0.03)
(0.01)
(0.003)
(0.20)
(0.03)
c’
-3.48
-3.62
-3.61
-3.58
-3.42
-3.59
-3.57
-3.54
(1.35)** (1.36)** (1.34)** (1.34)** (1.35)** (1.36)** (1.34)** (1.33)**
c
-3.62
-3.62
-3.62
-3.62
-3.62
-3.62
-3.62
-3.62
(1.33)** (1.33)** (1.33)** (1.33)** (1.33)** (1.33)** (1.33)** (1.33)**
IE
0.0004
-0.0001
-0.0004
0.0000
0.003
0.0004
0.002
-0.002
(0.06)
(0.07)
(0.05)
(0.04)
(0.03)
(0.05)
(0.04)
(0.02)
95% -0.1110, -0.1675, -0.1100, -0.0966, -0.0487,
-0.1025, -0.0673, -0.0497,
CIs
0.1276,
0.1333
0.0652
0.0647
0.0715
0.1032,
0.1186
0.0492
†p<0.10, *p<0.05, **p<0.01

Note. Bifido = Bifidobacterium, IE = Indirect Effect of the serial mediation, IL-1β = Interleukin1 Beta, IL-6 = Interleukin-6, IL-8 = Interleukin-8, Lacto = Lactobacillus, STAI-Trait = StateTrait Anxiety Inventory-Trait, TNF-α = Tumor Necrosis Factor Alpha. 95 % CIs = the upper and
lower 95 % confidence intervals.
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Table 15. Unstandardized Path Coefficients (standard error) for Serial Mediation Model of
DHA on STAI-Trait
à
à
à
Lacto
Lacto
Lacto
Lactoà Bifidoà Bifidoà
Bifido Bifidoà
àIL-6
IL-1β
IL-8
IL-6
TNF
IL-1β
IL-8
TNF
a1
0.12
0.12
0.12
0.12
-0.11
-0.11
-0.11
-0.11
(0.41)
(0.41)
(0.41)
(0.41)
(0.59)
(0.59)
(0.59)
(0.59)
a2
-50.87
-116.13
-0.50
-0.02
-50.56
-106.42
-0.43
0.12
(40.27)
(75.84)
(1.16)
(6.87)
(40.20)
(78.55)
(1.17)
(6.85)
d
8.59
59.15
0.43
-0.13
-6.91
21.57
0.17
-0.73
(12.28) (23.14)**
(0.35)
(2.10)
(8.49)
(16.59)
(0.25)
(1.45)
b1
0.23
0.27
0.32
0.25
0.38
0.35
0.37
0.32
(0.56)
(0.59)
(0.57)
(0.56)
(0.39)
(0.39)
(0.39)
(0.38)
b2
0.004
-0.0003
-0.12
-0.03
0.01
-0.0003
-0.12
-0.03
(0.01)
(0.003)
(0.20)
(0.03)
(0.01)
(0.003)
(0.20)
(0.03)
c’
-4.70
-4.93
-4.96
-4.90
-4.60
-4.86
-4.88
-4.83
(1.85)** (1.87)** (1.83)** (1.82)**
(1.84)*
(1.85)** (1.82)** (1.81)**
c
-4.87
-4.87
-4.87
-4.87
-4.87
-4.87
-4.87
-4.87
(1.81)** (1.81)** (1.81)** (1.81)** (1.81)** (1.81)** (1.81)** (1.81)**
IE
0.004
-0.002
-0.01
0.001
0.003
0.001
0.002
-0.002
(0.09)
(0.10)
(0.08)
(0.05)
(0.04)
(0.07)
(0.06)
(0.04)
95% -0.1330, -0.2405, -0.1760, -0.1385, -0.0733,
-0.1514, -0.0960, -0.0729,
CIs
0.2329
0.2022
0.0959
0.0853
0.0895
0.1399
0.1587
0.0647
†p<0.10, *p<0.05, **p<0.01

Note. Bifido = Bifidobacterium, DHA = Docosahexaenoic Acid, IE = Indirect Effect of the serial
mediation, IL-1β = Interleukin-1 Beta, IL-6 = Interleukin-6, IL-8 = Interleukin-8, Lacto =
Lactobacillus, STAI-Trait = State-Trait Anxiety Inventory-Trait, TNF-α = Tumor Necrosis
Factor Alpha. 95 % CIs = the upper and lower 95 % confidence intervals.

125
Table 16. Unstandardized Path Coefficients (standard error) for Serial Mediation Model of EPA
on STAI-Trait
à
à
à
Lacto
Lacto
Lacto
Lactoà Bifidoà Bifidoà Bifidoà Bifidoà
IL-1β
IL-8
IL-6
TNF
IL-1β
IL-8
IL-6
TNF
a1
-1.30
-1.30
-1.30
-1.30
-0.81
-0.81
-0.81
-0.81
(1.40)
(1.40)
(1.40)
(1.40)
(2.03)
(2.03)
(2.03)
(2.03)
a2
-51.94
-62.62
8.27
28.13
-67.15
-119.19
7.77
27.41
(141.55) (268.27) (3.89)* (23.61)
(140.49)
(275.15)
(3.92)*
(23.45)
d
7.48
57.17
0.51
-0.16
-6.86
21.72
0.20
-0.65
(12.50) (23.68)*
(0.34)
(2.08)
(8.59)
(16.81)
(0.24)
(1.43)
b1
0.04
0.02
0.08
0.08
0.37
0.32
0.33
0.32
(0.58)
(0.60)
(0.59)
(0.58)
(0.39)
(0.40)
(0.40)
(0.40)
b2
0.01
0.001
0.004
-0.02
0.01
0.001
0.01
-0.02
(0.01)
(0.003)
(0.21)
(0.03)
(0.01)
(0.003)
(0.21)
(0.03)
c’
-12.03
-12.25
-12.35
-11.66
-11.74
-12.07
-12.08
-11.56
(6.51)†
(6.55)†
(6.78)† (6.60)†
(6.44)†
(6.49)†
(6.68)†
(6.53)†
c
-12.42
-12.42
-12.42
-12.42
-12.42
-12.42
-12.42
-12.42
(6.41)†
(6.41)†
(6.41)† (6.41)†
(6.41)†
(6.41)†
(6.41)†
(6.41)†
IE
-0.05
-0.08
-0.003
0.005
0.03
-0.01
0.001
-0.01
(0.26)
(0.34)
(0.30)
(0.22)
(0.17)
(0.22)
(0.20)
(0.11)
95% -0.8949, -0.9434, -0.7019, -0.6500, -0.2867,
-0.4555, -0.3163, -0.1639,
CIs
0.0561
0.5371
0.3789
0.2444
0.3771
0.3986
0.4280
0.2219
†p<0.10, *p<0.05, **p<0.01

Note. Bifido = Bifidobacterium, EPA = Eicosapentaenoic Acid, IE = Indirect Effect of the serial
mediation, IL-1β = Interleukin-1 Beta, IL-6 = Interleukin-6, IL-8 = Interleukin-8, Lacto =
Lactobacillus, STAI-Trait = State-Trait Anxiety Inventory-Trait, TNF-α = Tumor Necrosis
Factor Alpha. 95 % CIs = the upper and lower 95 % confidence intervals.
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Table 17. Unstandardized Path Coefficients (standard error) for Serial Mediation Model of
ALA on STAI-Trait
à
à
à
Lacto
Lacto
Lacto
Lactoà Bifidoà Bifidoà
Bifido Bifidoà
àIL-6
IL-1β
IL-8
IL-6
TNF
IL-1β
IL-8
TNF
a1
-1.39
-1.39
-1.39
-1.39
0.66
0.66
0.66
0.66
(1.79)
(1.79)
(1.79)
(1.79)
(2.59)
(2.59)
(2.59)
(2.59)
a2
-131.10
-154.61
0.51
-15.33
-136.73
-248.17
-0.20
-14.55
(179.99) (341.77)
(5.14)
(30.39) (178.92)
(350.54)
(5.15)
(30.21)
d
7.14
56.78
0.43
-0.23
-6.45
22.46
0.18
-0.71
(12.43) (23.61)*
(0.35)
(2.10)
(8.56)
(16.76)
(0.25)
(1.44)
b1
0.17
0.15
0.26
0.21
0.41
0.34
0.38
0.34
(0.59)
(0.62)
(0.60)
(0.59)
(0.40)
(0.41)
(0.41)
(0.41)
b2
0.01
0.001
-0.09
-0.03
0.01
0.001
-0.10
-0.03
(0.01)
(0.003)
(0.21)
(0.04)
(0.01)
(0.003)
(0.21)
(0.04)
c’
3.20
2.57
2.42
1.89
2.79
2.10
1.81
1.39
(8.54)
(8.59)
(8.57)
(8.55)
(8.45)
(8.53)
(8.49)
(8.47)
c
2.07
2.07
2.07
2.07
2.07
2.07
2.07
2.07
(8.42)
(8.42)
(8.42)
(8.42)
(8.42)
(8.42)
(8.42)
(8.42)
IE
-0.06
-0.10
0.06
-0.01
-0.03
0.02
-0.01
0.01
(0.39)
(0.38)
(0.35)
(0.25)
(0.16)
(0.20)
(0.17)
(0.11)
95% -1.3148, -0.7724, -0.2739, -0.5683, -0.4001,
-0.4469, -0.4754, -0.2498,
CIs
0.1945
0.7518
0.5357
0.3897
0.2445
0.3690
0.1745
0.2221
†p<0.10, *p<0.05, **p<0.01

Note. ALA = Alpha-linolenic Acid, Bifido = Bifidobacterium, IE = Indirect Effect of the serial
mediation, IL-1β = Interleukin-1 Beta, IL-6 = Interleukin-6, IL-8 = Interleukin-8, Lacto =
Lactobacillus, STAI-Trait = State-Trait Anxiety Inventory-Trait, TNF-α = Tumor Necrosis
Factor Alpha. 95 % CIs = the upper and lower 95 % confidence intervals.
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Table 18. Unstandardized Path Coefficients (standard error) for Serial Mediation Model of
Omega-3 Index on BDI
à
à
Lacto
Lacto
Lactoà Lactoà Bifidoà Bifidoà
Bifido Bifidoà
àIL-6
IL-1β
IL-8
IL-6
TNF
IL-1β
IL-8
TNF
a1
0.01
0.01
0.01
0.01
-0.11
-0.11
-0.11
-0.11
(0.30)
(0.30)
(0.30)
(0.30)
(0.43)
(0.43)
(0.43)
(0.43)
a2
-33.75
-74.52
0.11
1.39
-34.39
-71.53
0.13
1.31
(29.59)
(55.83)
(0.85)
(5.03)
(29.55)
(57.77)
(0.86)
(5.03)
d
8.07
57.96
0.42
-0.13
-6.96
21.45
0.18
-0.72
(12.30)
(23.22)*
(0.35)
(2.09)
(8.50)
(16.63)
(0.25)
(1.45)
b1
0.53
0.50
0.56
0.57
0.29
0.21
0.25
0.24
(0.36)
(0.38)
(0.37)
(0.37)
(0.25)
(0.26)
(0.26)
(0.26)
b2
0.004
0.001
0.01
-0.02
0.01
0.002
0.03
-0.02
(0.004)
(0.002)
(0.13)
(0.02)
(0.004)
(0.002)
(0.13)
(0.02)
c’
-1.72
-1.79
-1.88
-1.85
-1.65
-1.72
-1.84
-1.82
(0.88)†
(0.90)*
(0.89)*
(0.89)*
(0.89)†
(0.90)†
(0.90)*
(0.89)*
c
-1.87
-1.87
-1.87
-1.87
-1.87
-1.87
-1.87
-1.87
(0.89)*
(0.89)*
(0.89)*
(0.89)*
(0.89)*
(0.89)*
(0.89)*
(0.89)*
IE
0.0005
0.0008
0.0000
0.0000
0.004
-0.004
-0.0005
-0.002
(0.04)
(0.05)
(0.05)
(0.03)
(0.03)
(0.04)
(0.03)
(0.02)
95% -0.0702, -0.1335, -0.1192, -0.0859, -0.0541,
-0.1053, -0.0572, -0.0439,
CIs
0.0749
0.0791,
0.0451
0.0501
0.0737,
0.0573
0.0503
0.0371
†p<0.10, *p<0.05, **p<0.01

Note. BDI = Beck Depression Inventory, Bifido = Bifidobacterium, IE = Indirect Effect of the
serial mediation, IL-1β = Interleukin-1 Beta, IL-6 = Interleukin-6, IL-8 = Interleukin-8, Lacto =
Lactobacillus, TNF-α = Tumor Necrosis Factor Alpha. 95 % CIs = the upper and lower 95 %
confidence intervals.
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Table 19. Unstandardized Path Coefficients (standard error) for Serial Mediation Model of
DHA on BDI
à
à
à
Lacto
Lacto
Lacto
Lactoà Bifidoà Bifidoà
Bifido Bifidoà
àIL-6
IL-1β
IL-8
IL-6
TNF
IL-1β
IL-8
TNF
a1
0.12
0.12
0.12
0.12
-0.11
-0.11
-0.11
-0.11
(0.41)
(0.41)
(0.41)
(0.41)
(0.59)
(0.59)
(0.59)
(0.59)
a2
-50.87
-116.13
-0.50
-0.02
-50.56
-106.42
-0.43
0.12
(40.27)
(75.84)
(1.16)
(6.87)
(40.20)
(78.55)
(1.17)
(6.85)
d
8.59
59.15
0.43
-0.13
-6.91
21.57
0.17
-0.73
(12.38) (23.14)**
(0.35)
(2.10)
(8.49)
(16.59)
(0.25)
(1.45)
b1
0.55
0.53
0.60
0.59
0.29
0.22
0.25
0.24
(0.37)
(0.39)
(0.37)
(0.37)
(0.26)
(0.26)
(0.26)
(0.26)
b2
0.005
-0.001
-0.01
-0.02
0.01
0.002
0.01
-0.02
(0.004)
(0.002)
(0.13)
(0.02)
(0.004)
(0.002)
(0.13)
(0.02)
c’
-2.23
-2.34
-2.47
-2.47
-2.09
-2.19
-2.36
-2.37
(1.21)†
(1.23)†
(1.21)*
(1.20)*
(1.22)†
(1.24)†
(1.23)†
(1.22)†
c
-2.40
-2.40
-2.40
-2.40
-2.40
-2.40
-2.40
-2.40
(1.22)*
(1.22)*
(1.22)*
(1.22)*
(1.22)*
(1.22)*
(1.22)*
(1.22)*
IE
0.005
0.008
-0.0005
0.0003
0.004
-0.004
-0.0002
-0.002
(0.07)
(0.08)
(0.07)
(0.05)
(0.04)
(0.05)
(0.03)
(0.03)
95% -0.0961, -0.1884, -0.1438, -0.1294, -0.0745,
-0.1338, -0.0711, -0.0649,
CIs
0.1646
0.1363
0.0633
0.0871
0.0922
0.0768
0.0665
0.0478
†p<0.10, *p<0.05, **p<0.01

Note. BDI = Beck Depression Inventory, Bifido = Bifidobacterium, DHA = Docosahexaenoic
Acid, IE = Indirect Effect of the serial mediation, IL-1β = Interleukin-1 Beta, IL-6 = Interleukin6, IL-8 = Interleukin-8, Lacto = Lactobacillus, TNF-α = Tumor Necrosis Factor Alpha. 95 % CIs
= the upper and lower 95 % confidence intervals.
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Table 20. Unstandardized Path Coefficients (standard error) for Serial Mediation Model of EPA
on BDI
à
à
à
Lacto
Lacto
Lacto
Lactoà Bifidoà Bifidoà Bifidoà Bifidoà
IL-1β
IL-8
IL-6
TNF
IL-1β
IL-8
IL-6
TNF
a1
-1.30
-1.30
-1.30
-1.30
-0.81
-0.81
-0.81
-0.81
(1.40)
(1.40)
(1.40)
(1.40)
(2.03)
(2.03)
(2.03)
(2.03)
a2
-51.94
-62.62
8.27
28.13
-67.15
-119.19
7.77
27.41
(141.55) (268.27) (3.89)* (23.61)
(140.49)
(275.15)
(3.92)*
(23.45)
d
7.48
57.17
0.51
-0.16
-6.86
21.72
0.20
-0.65
(12.50) (23.68)*
(0.34)
(2.08)
(8.59)
(16.81)
(0.24)
(1.43)
b1
0.45
0.39
0.46
0.50
0.29
0.20
0.23
0.23
(0.37)
(0.39)
(0.38)
(0.37)
(0.26)
(0.26)
(0.26)
(0.26)
b2
0.01
0.002
0.07
-0.02
0.01
0.002
0.08
-0.02
(0.004)
(0.002)
(0.14)
(0.02)
(0.004)
(0.002)
(0.14)
(0.02)
c’
-6.91
-7.08
-7.74
-6.72
-7.21
-7.38
-8.28
-7.22
(4.18)†
(4.23)†
(4.39)†
(4.28)
(4.17)†
(4.22)†
(4.37)†
(4.28)†
c
-7.83
-7.83
-7.83
-7.83
-7.83
-7.83
-7.83
-7.83
(4.21)†
(4.21)†
(4.21)† (4.21)†
(4.21)†
(4.21)†
(4.21)†
(4.21)†
IE
-0.05
-0.13
-0.04
0.003
0.03
-0.04
-0.01
-0.008
(0.16)
(0.21)
(0.23)
(0.19)
(0.15)
(0.17)
(0.16)
(0.10)
95% -0.5315, -0.7117, -0.6706, -0.5753, -0.2524,
-0.3998, -0.3492, -0.1687,
CIs
0.0770
0.1232
0.1930
0.1223
0.3632
0.3073
0.2817
0.2075
†p<0.10, *p<0.05, **p<0.01

Note. BDI = Beck Depression Inventory, Bifido = Bifidobacterium, EPA = Eicosapentaenoic
Acid, IE = Indirect Effect of the serial mediation, IL-1β = Interleukin-1 Beta, IL-6 = Interleukin6, IL-8 = Interleukin-8, Lacto = Lactobacillus, TNF-α = Tumor Necrosis Factor Alpha. 95 % CIs
= the upper and lower 95 % confidence intervals.
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Table 21. Unstandardized Path Coefficients (standard error) for Serial Mediation Model of ALA
on BDI
à
à
à
Lacto
Lacto
Lacto
Lactoà Bifidoà Bifidoà
Bifido Bifidoà
àIL-6
IL-1β
IL-8
IL-6
TNF
IL-1β
IL-8
TNF
a1
-1.39
-1.39
-1.39
-1.39
0.66
0.66
0.66
0.66
(1.79)
(1.79)
(1.79)
(1.79)
(2.59)
(2.59)
(2.59)
(2.59)
a2
-131.10
-154.61
0.51
-15.33
-136.73
-248.17
-0.20
-14.55
(179.99) (341.77)
(5.14)
(30.39) (178.92)
(350.54)
(5.15)
(30.21)
d
7.14
56.78
0.43
-0.23
-6.45
22.46
0.18
-0.71
(12.43)
(23.61)*
(0.35)
(2.10)
(8.56)
(16.76)
(0.25)
(1.44)
b1
0.52
0.46
0.56
0.55
0.31
0.22
0.27
0.26
(0.38)
(0.40)
(0.39)
(0.38)
(0.26)
(0.27)
(0.27)
(0.26)
b2
0.01
0.002
0.01
-0.02
0.01
0.002
0.02
-0.02
(0.004)
(0.002)
(0.13)
(0.02)
(0.004)†
(0.002)
(0.14)
(0.03)
c’
-0.01
-0.48
-0.76
-1.10
-0.83
-1.16
-1.71
-2.02
(5.47)
(5.51)
(5.54)
(5.51)
(5.47)
(5.53)
(5.57)
(5.54)
c
-1.54
-1.54
-1.54
-1.54
-1.54
-1.54
-1.54
-1.54
(5.52)
(5.52)
(5.52)
(5.52)
(5.52)
(5.52)
(5.52)
(5.52)
IE
-0.06
-0.14
-0.003
-0.007
-0.03
0.03
0.003
0.001
(0.26)
(0.24)
(0.23)
(0.18)
(0.14)
(0.16)
(0.13)
(0.01)
95% -0.8366,
-0.5228, -0.2807, -0.4547, -0.3305,
-0.3305, -0.2353, -0.1983,
CIs
0.1427
0.4035
0.3106
0.2656
0.2348
0.3674
0.2186
0.1826
†p<0.10, *p<0.05, **p<0.01

Note. ALA = Alpha-linolenic Acid, BDI = Beck Depression Inventory, Bifido =
Bifidobacterium, IE = Indirect Effect of the serial mediation, IL-1β = Interleukin-1 Beta, IL-6 =
Interleukin-6, IL-8 = Interleukin-8, Lacto = Lactobacillus, TNF-α = Tumor Necrosis Factor
Alpha. 95 % CIs = the upper and lower 95 % confidence intervals.
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Figure 1. Inflammation as a hypothesized mechanism of action explaining the relationship
between ω-3 FAs and anxiety and depression.
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Figure 2. Proposed path analysis examining inflammation and gut bacteria as a hypothesized
mechanism of action explaining the relationship between ω-3 FAs and stress symptoms.
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Figure 3. Proposed path analysis examining inflammation and gut bacteria as a hypothesized
mechanism of action explaining the relationship between ω-3 FAs and anxiety symptoms.
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Figure 4. Proposed path analysis examining inflammation and gut bacteria as a hypothesized
mechanism of action explaining the relationship between ω-3 FAs and depression symptoms.
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Figure 5. Proposed serial mediation model, key for mediation results in Aim 2.

